A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With Acute Myeloid Leukemia Undergoing Remission Induction Therapy
Phase: PHASE2
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia
Sponsor: Case Comprehensive Cancer Center

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
1 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
 
 
STUDY NUMBER: CASE 4913 
(Novartis CETB115DUS02T) 
Protocol Version: 
Version 6 
Date of Protocol 
May 14, 2018
STUDY TITLE: A Single Arm, Phase II study of Eltrombopag to Enhance Platelet Count 
Recovery in Elderly Patients with Acute Myeloid Leukemia undergoing Remission Induction 
therapy 
ClinicalTrials.gov #: NCT02071901 
PRINCIPAL INVESTIGATOR: 
Sudipto Mukherjee, MD, PhD, MPH 
9500 Euclid Avenue 
CA-62 
Cleveland, Ohio 44195 
Telephone: (216) 444-0506 
Fax: (216) 444-9464 
E-mail address: mukhers2@ccf.org 
 
 
CO- INVESTIGATORS: 
Department of Hematologic Oncology and Blood Disorders 
Taussig Cancer Institute 
Cleveland Clinic 
Mikkael Sekeres, MD 
Anjali Advani, MD 
Yogen Saunthararajah, MD  
Aaron Gerds, MD 
Betty Hamilton, MD 
Ronald Sobecks, MD  
Keith McCrae, MD 
Aziz Nazha, MD 
Hetty Carraway, MD

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
2 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
STATISTICIAN: 
Brian Hobbs, PhD 
 
Taussig Cancer Institute 
10201 Carnegie Ave., CA-60 
Cleveland, Ohio 44195 
Telephone: (216) 444-3738 
 Fax: (216) 444-9464 
E-mail address: hobbsb@ccf.org  
 
 
 
SPONSOR: 
Case Comprehensive Cancer Center (Novartis will supply 
PROMACTA® eltrombopag) 
 
CLINICAL FACILITY: 
     Cleveland Clinic 
 
APPROVALS: 
Protocol Review and Monitoring Committee 
Cleveland Clinic IRB 
 
 
 
STUDY COORDINATOR: 
Benjamin Pannell 
Department of Hematologic Oncology and Blood Disorders 
Taussig Cancer Institute 
Cleveland Clinic 
9500 Euclid Avenue, JJN2 
Cleveland, OH 44195 
 
 
 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
3 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
SUMMARY OF CHANGES 
 
Version date/# 
Section # 
Description of change (s) 
V1, 6/11/2013 
 
Initial IRB Approval 
V2, 3/17/2015 
3, 6, 7, 8, 9 
1) clarification of inclusion/exclusion criteria; 2) addition 
of safety information; 3) changes to treatment/dosing 
V3, 4/28/2016 
3, 8, 10 
1) clarification of inclusion/exclusion criteria; 2) updated 
to off study monitoring; 3) revisions to study endpoints 
V4, 6/21/2017 
3, 4, 5, 7, 8, 10, 11 
1) administrative/formatting changes throughout the 
protocol; 2) changed drug supplier from GSK to 
Novartis; 3) clarification of inclusion/exclusion criteria; 
4) minor revision to study design/data collection; 5) 
revised study calendar; 6) clarification of defined 
complete response 
V5, 8/8/2017 
3, 4.1, 8, 9, 11.7 
1) clarification of inclusion/exclusion criteria; 2) blood 
transfusion support in the study design; 3) updated 
treatment plan information; 4) revised ancillary 
laboratory test schedule; 5) AE collection period 
correction 
V6, 5/14/2018 
3.2 
1) minor formatting and administrative edits throughout 
the protocol; 2) modified exclusion criteria #10 and 
removed exclusion criteria #11 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
4 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
Table of Contents 
1.0 
BACKGROUND AND RATIONALE ............................................................................ 5 
2.0 
STUDY OBJECTIVES ..................................................................................................... 10 
3.0 
SELECTION OF PATIENTS ........................................................................................ 11 
4.0 
STUDY DESIGN ............................................................................................................. 13 
5.0 
STUDY TREATMENTS ................................................................................................ 14 
6.0 
SAFETY DATA ANDASSESSMENT .......................................................................... 17 
7.0 
TREATMENT PLAN ...................................................................................................... 20 
8.0 
CLINICAL MONITORING .......................................................................................... 25 
9.0 
ANCILLARY LABORATORY RESEARCH STUDIES ........................................... 30 
10.0 
STUDY ENDPOINTS ..................................................................................................... 30 
11.0 
ADVERSE EVENTS ...................................................................................................... 33 
12.0 
STATISTICAL CONSIDERATIONS .......................................................................... 40 
13.0 
REGULATORY CONSIDERATIONS ........................................................................ 41 
14.0 
REFERENCES................................................................................................................43 
APPENDIX I. WHO BLEEDING SCALE ........................................................................................... 46 
APPENDIX II. ECOG PERFORMANCE STATUS ......................................................................... 47 
APPENDIX III. AML INTERNATIONAL WORKING GROUP RESPONSE CRITERIA ................. 48 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
5 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
1.0 BACKGROUND AND STUDY RATIONALE 
 
1.1 Acute Myeloid Leukemia 
 
Acute myeloid leukemia (AML) presents at all ages, but is mainly a disease of older adults, with 
a median age of 67 years in the US population.(1) In the Swedish Acute Leukemia Registry, 68% 
of patients diagnosed with AML since 1973 were over age 60 years; between 1997 and 2005, 
75% were aged 60 years or more.(2) Prognosis worsens with every subsequent decade beginning 
at age 30.(1,3) In a multivariate analysis of prognostic factors, age ≥ 60 years has consistently 
been shown to be a significant poor prognostic factor for complete remission (CR), overall 
survival (OS), remission duration, and relapse-free survival (RFS). Population-based studies 
have reported 3- and 5-year survival rates of only 9% to 10% and 3% to 8%, respectively, in 
patients over aged 60 and over, compared with 5-year survival rates of up to 50% for younger 
patients.(2,4,5) Poorer outcome is likely the result of less intensive therapy in this population, 
concurrent comorbidities, a higher likelihood of underlying hematopoietic disorders, and 
biologically poor risk disease. Once CR has been obtained, there is no standard postremission 
strategy in these patients. No prospective randomized study has ever established the benefit of 
postremission therapy in older adults; however, all large studies of AML have included 
postremission therapy out of concern that patients are all destined to relapse without 
postremission therapy, and no long-term survivors among older adults have achieved that status 
without post-remission therapy. 
 
In older patients inability to achieve CR, particularly as a result of delayed platelet recovery, can 
lead to prolonged dependence on platelet transfusions, risk of bleeding and most importantly, 
inability to proceed with post-remission therapy. Recent data from M. D. Anderson Cancer 
Center and the Southwest Oncology Group showed that patients achieving CR were more likely 
to be alive at 3, and particularly at 5 years than patients achieving partial complete remission 
(CRp) (relative risk for 5-year survival, 3.0; 95% CI, 1.0 to 9.0; P < .02).(6) A multivariate 
analysis in the same cohort that adjusted for covariates including age at diagnosis, cytogenetics, 
prior chemotherapy, antecedent hematologic disorder (AHD), poor performance status, response 
(ie, CR, CRp) indicated that CR was independently associated with a longer relapse-free survival 
and OS relative to CRp. Leukemia patients not cured almost uniformly die from sequelae of 
being immunocompromised, thrombocytopenic, or both. It stands to reason that abrogation of 
periods of cytopenia following remission induction therapy could reduce complications, which in 
turn could lead to better outcomes for older adults. 
 
1.2 PROMACTA® (Eltrombopag) 
 
1.2.1 Scientific Background 
 
TPO is the principal cytokine involved in the regulation of megakaryopoiesis and platelet 
production. Native TPO is a 60–70 kDa heavily glycosylated polypeptide of 332 amino acids 
produced by the liver parenchymal, bone marrow and sinusoidal epithelial kidney cells and is the 
natural ligand for the TPO-receptor.(7) Eltrombopag is an orally bioavailable, small molecule, 
TPO-R agonist that stimulates platelet production by a mechanism similar, but not identical to 
endogenous TPO. Eltrombopag selectively interacts with the transmembrane domain of the TPO- 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
6 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
R expressed on the surface of megakaryocytes and their precursor cells (8) at a site different  
from native TPO, resulting in activation of various signal transduction pathways.(9) The 
resulting changes in gene expression commit bone marrow progenitor cells towards the 
megakaryocytic pathway, leading to release of normally functioning platelets into the peripheral 
circulation. Unlike native TPO, eltrombopag does not cause platelet aggregation and 
degranulation.(10) Because eltrombopag is not a protein, it is not immunogenic and does not 
induce formation of neutralizing antibodies. As of 13 February 2012, eltrombopag has been 
approved for the treatment of chronic idiopathic thrombocytopenic purpura (ITP) in 84 countries. 
Two Phase III studies have been completed (TPL103922/ENABLE 1 and TPL108390/ENABLE 
2) in subjects with HCV-related thrombocytopenia. Based on these study findings eltrombopag is 
the first supportive care treatment approved for patients with thrombocytopenia with chronic 
hepatitis C to allow the initiation and maintenance of interferon-based therapy. 
 
 
1.2.2 Pre-Clinical Studies 
 
The details of pre-clinical and clinical pharmacology data are available in the Clinical 
Investigator’s Brochure (CIB) provided by Novartis.(11) There is a theoretical concern that 
stimulation of the TPO receptor on the surface of hematopoietic cells may also increase the risk 
for hematologic malignancies. As such, extensive preclinical research to ascertain any potential 
relationship between treatment with eltrombopag and proliferation of malignant cells has been 
performed. Based on this research, there is no evidence in cell lines or in AML/MDS patient 
samples that eltrombopag stimulates malignant growth. In several independently conducted 
experiments (12-15), it has been consistently demonstrated that eltrombopag can inhibit the 
proliferation of leukemic cells at high concentrations (3-5x higher than used in ITP). These 
concentrations are expected to be reached in patients with MDS and AML following once daily 
administration of 200 to 300 mg of eltrombopag. 
 
In contrast to the stimulating effects of eltrombopag on megakaryocytes, eltrombopag decreased 
the growth of 16 different leukemia and lymphoma cell lines in vitro.(13) The decrease in 
proliferation was due to death of the cells by a mechanism other than apoptosis. There was no 
significant effect on the differentiation of the leukemic cell lines. While recombinant TPO 
caused a small increase in the proliferation of lymphoblastic T-cell leukemia, eltrombopag did 
not induce a similar increase, but rather inhibited proliferation, even in the presence of TPO. 
While G-CSF increased the proliferation of OCI AML2 cells, eltrombopag decreased the 
proliferation. 
 
Recently, a proliferation assay comparing the effects of eltrombopag and recombinant TPO has 
been conducted in 5 leukemic cell lines (Figure 1). Eltrombopag, but not recombinant TPO, had 
anti-leukemic effects in the 5 cell lines. 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
7 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
Figure 1. Effects of eltrombopag on OCI-AML3 cell line proliferation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The IC50 for eltrombopag in these preclinical experiments ranged from 6.4 to 14.2 g/mL 
(Table 3). Based upon preliminary pharmacokinetic data from patients with MDS/AML in Part 
1 of this study (n=7), the median eltrombopag steady-state Cmax and pre-dose trough 
concentrations after once daily administration of 100 mg eltrombopag were 13.5 and 4.13 
g/mL, respectively. As the PK of eltrombopag has been shown to be dose proportional, it is 
expected that doses of 200 to 300 mg eltrombopag in patients with MDS/AML will result in 
plasma concentrations at or above the IC50 values identified for anti-leukemic effects in the cell 
lines. 
 
Table 3 
Eltrombopag IC50 Values 
Leukemic Cell Line 
IC50 ± Std Dev (g/mL) 
HL-60 
6.4 ± 0.4 
HEL 92.1.7 
8.0 ± 1.0 
OCI-AML3 
9.8 ± 1.8 
THP-1 
13.5 ± 1.0 
NOMO 
13.5 ± 1.2 
N2C-TPO 
14.2 ± 1.7 
 
 
The anti-proliferative effect on hematologic malignancies was investigated further in several 
additional experiments using bone marrow mononuclear cell (BM-MNC) samples from 10 
patients with AML or MDS.(12) A decrease in malignant cell number was seen in 8 of 10 
samples, while the cell number for 2 samples remained unchanged, after two weeks treatment 
with eltrombopag. The anti-proliferative effects did not reach statistical significance due to inter- 
individual variation. There was no significantly decreased apoptosis, no increased immature cells 
or blasts, nor any evidence of increased long-term self-renewal of AML or MDS BM-MNC in 
any of the samples. To test anti-proliferative effects of eltrombopag in animals (as eltrombopag 
only interacts with the human TPO-R), the following ex-vivo experiment was conducted. BM 
MNC from 3 patients with AML were transplanted into 3 cohorts of sublethally irradiated NOG 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
8 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
mice. Successfully transplanted mice were treated with or without eltrombopag. Confirming the 
results from the in vitro assays, treatment with eltrombopag did not enhance the in vivo 
engraftment of human AML cells in this xenotransplantation model.(12) 
 
Recently, the same group has published that eltrombopag, at clinically achievable concentrations, 
inhibits proliferation and induces differentiation of leukemic cells through reduction of 
intracellular iron levels, independently of the TPO-R.(15) In vivo, eltrombopag prolonged 
survival in 2 murine models of leukemia. The anti-proliferative effects of chemotherapy in 
leukemic cell lines was enhanced by co-incubation with eltrombopag.(15) The authors showed 
that in contrast to eltrombopag, recombinant human TPO and another TPO-R agonist, 
romiplostim, do not modulate intracellular iron levels. 
 
Similar results were observed by another independent study group using eltrombopag and a 
small molecule TPO receptor agonist that is very similar to eltrombopag.(16) In another 
independent investigation, bone marrow samples from 5 patients with MDS who had a 
low/intermediate-1-risk IPSS score were treated in vitro with eltrombopag, again demonstrating 
anti-proliferative effects upon co-incubation with eltrombopag.(14) 
 
Please refer to the current version of the CIB (11) for further information regarding pre-clinical 
and clinical pharmacology studies. 
 
1.2.3 Clinical Studies 
 
Eltrombopag has been administered both to healthy volunteers and subjects with 
thrombocytopenia from a variety of etiologies, and it has been shown to improve platelet counts 
in those with thrombocytopenia. A total of 664 subjects have received eltrombopag in 16 clinical 
pharmacology studies, including 618 healthy subjects, 25 subjects with hepatic impairment and 
21 subjects with renal impairment. Over 2400 subjects have received eltrombopag in completed 
or ongoing GSK-sponsored clinical efficacy studies in ITP, chronic liver disease or 
hematologic/oncologic malignancies globally. 
 
Study PMA112509, a Phase I/II study of eltrombopag in thrombocytopenic subjects with 
advanced MDS or AML is currently ongoing. Part 1 of TRC114968 enrolled 17 subjects; 11 
subjects completed the 8 weeks of treatment in Part 1. Preliminary safety data is available. Six 
subjects discontinued treatment early, 5 due to adverse events (AEs; 2 Grade 3 alanine 
aminotransferase [ALT] increase, 1 Grade 3 Nausea, 1 Grade 4 Laryngeal edema, 1 Grade 5 
Sepsis, and 1 Grade 3 Gastrointestinal hypomotility) and 1 due to investigator discretion. Of the 
11 subjects who completed Part 1, 5 entered the extension (Part 3). The most common AEs (in at 
least 3 subjects) were pyrexia, ALT increased, diarrhea, epistaxis, headache and pneumonia. 
Seven subjects reported 15 serious adverse events (SAEs; cystitis and hematuria; respiratory tract 
infection and sepsis; cerebral hemorrhage and pyrexia; ALT increased; cellulitis and hemolytic 
anemia; pyrexia, gastrointestinal hypomotility and vertigo; pneumonia, laryngeal edema and 
sepsis.). Reported AEs and SAEs were consistent with the disease under study and with those 
expected during treatment with eltrombopag. Three subjects died (2 – SAEs of sepsis and 1 – 
disease progression (not reported as an AE). 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
9 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
Preliminary pharmacokinetic data from the first 7 subjects enrolled in Part 1 of this study showed 
the median eltrombopag steady-state Cmax and pre-dose trough concentration after once daily 
administration of 100 mg eltrombopag were 13.5 and 4.13 g/mL, respectively. These values are 
generally consistent with previous PK observations in healthy subjects and patients with ITP. As 
the PK of eltrombopag has been shown to be dose proportional, it is expected that doses of 200 
to 300 mg eltrombopag utilized in this study will result in plasma concentrations at or above 
these IC50 values for the majority of the dosing interval (predicted 200mg Cmax and trough 
concentrations: 27 and 8.26g/mL, respectively; predicted 300mg Cmax and trough 
concentrations: 40.5 and 12.39g/mL, respectively). Please refer to the current version of the 
CIB (11) for further information regarding clinical studies. 
 
One clinical trial assessing the role of eltrombopag in palliative setting in elderly AML patients 
(NCT01113502) recently completed recruitment and results are awaited. Several other 
eltrombopag trials are currently underway in MDS (lower- as well as in higher-risk disease) and 
in AML setting [NCT01286038, NCT01481220, NCT00961064, NCT01488565, NCT01440374, 
NCT00903422, NCT01550185]. 
 
1.3 Thrombocytopenia 
 
Thrombocytopenia is a common problem in patients with acute leukemia and other hematologic 
malignancies treated with intensive chemotherapy. The current standard treatment strategy to 
prevent or manage thrombocytopenia-associated bleeding complications relies exclusively on 
supportive platelet transfusions. However, this therapeutic approach is expensive, time 
consuming and associated with risks of alloimmunization and bloodstream infections. Moreover, 
the effects of platelet transfusions last only for 3-7 days.(17) The incidence of alloimmunization 
to platelets range from 9-50 % (18,19) and in these patients, platelet transfusions are ineffective 
in raising platelet counts. Although use of leukoreduced products has reduced the risk of 
alloimmunization, it still remains at about 4 %.(18) Other immune-mediated problems include 
febrile reactions and transfusion-related acute lung injury (TRALI). The reported incidence of 
febrile reaction ranges from 0.13 to 37.5 % per unit in hematology/oncology patients.(20) The 
incidence of TRALI in patients receiving high-volume plasma products including apheresed 
platelets has been reported to range from 1 in 1,300 to 1 in 5,000 transfusions.(21-23) In 
addition, there remains a risk of infections from platelet transfusions. Estimated residual risk of 
acquiring Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) from donations 
from repeat donors (after nucleic acid testing) is 1 per 1,935,000 and 1 per 2,135,000, 
respectively.(24) The chance of acquiring Hepatitis B virus infection is approximately 1 in 
200,000. The risk of bacterial transmission is approximately 1 in 50,000 apheresis platelets.(25, 
26) 
 
1.4 Rationale for using Eltrombopag in the Treatment of AML 
 
To date, there is no effective strategy for managing thrombocytopenia in AML patients following 
induction chemotherapy (IC) other than supportive platelet transfusions, which are limited by 
supply, cost and transfusion refractoriness. Eltrombopag is capable of enhancing 
megakaryopoiesis without stimulating leukemic blasts or activating platelets – properties that 
make it a candidate drug of choice for therapeutic intervention in the post-induction phase of 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
10 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
AML treatment. Early platelet count recovery following IC has significant clinical implications 
including decrease in thrombocytopenia-related bleeding complications, reduced necessity for 
platelet transfusions, improved complete remission rates and timely initiation of post-remission 
therapy - factors that present challenges particularly in the management of older patients. 
 
While most of the eltrombopag studies in AML are in the relapsed or refractory setting or in 
those unable to withstand aggressive induction chemotherapy, a phase 1/2 study has been opened 
to assess the efficacy of eltrombopag in AML patients undergoing consolidation therapy 
following achievement of CR. We propose a novel therapeutic strategy where eltrombopag will 
be used in older AML patients undergoing IC who have no morphologic evidence of disease on a 
day 14 bone marrow assessment, with the goal of accelerating platelet recovery. We hypothesize 
that as eltrombopag acts at a TPO receptor site which is different from the native TPO binding 
site, it will accelerate megakaryopoiesis by acting synergistically with endogenous TPO, the 
levels of which have been shown to rise twenty-fold with drop in platelet counts below 50000/µL 
in AML patients while undergoing cytotoxic chemotherapy.(27) Our proposed use of 
eltrombopag in AML-associated thrombocytopenia thus represents a shift in treatment paradigm, 
with expected benefits in terms of decreased treatment-related morbidity, cost and potentially 
improved disease outcome. Currently, there are no competing trials in the public domain for this 
proposed study. 
 
 
2.0 
STUDY OBJECTIVES 
 
2.1 Primary Objective 
 
To determine whether eltrombopag leads to early platelet recovery in older AML patients (> 60 
years) who attain morphologic remission on day 14 (range, day 14-17) bone marrow assessment 
following remission IC. 
 
2.2 Secondary Objectives 
 
2.2.1 
To determine the effect of eltrombopag on megakaryopoiesis - median time to reach 
platelet count ≥ 50,000 /µ L and ≥ 100,000 /µ L, number of days of platelet transfusion, rates of 
platelet transfusion-independence and the median time to reach platelet transfusion- 
independence. 
 
2.2.2 
To determine the effect of eltrombopag on the rates of clinically significant bleeding events 
(CSBE) [Appendix I]. 
 
2.2.3 
To determine the effect of eltrombopag on erythropoiesis the median time to red blood cell 
transfusion independence. 
 
2.2.4 
To determine the effect of eltrombopag on granulopoiesis– the time taken to reach an 
absolute neutrophil count of > 500 /µL. 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
11 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
2.2.5 
To determine the safety and tolerability of eltrombopag in AML patients undergoing 
remission IC - incidence and severity of eltrombopag-related adverse events. 
2.2.6 
To determine the rates of CR, rates of CRp, time to attain CR, and time to initiation of 
postremission therapy. 
 
 
3.0 SELECTION OF PATIENTS 
 
3.1 Inclusion Criteria 
 
1. Patients must be > 60 years of age. 
 
2. All categories of AML will be included except for acute promyelocytic leukemia (APL) 
[AML-M3 as defined by 1976 French-American-British (FAB) classification, or APL with 
t(15;17)(q22;q12); PML-RARA as defined by the revised 2008 World Health Organization 
(WHO) classification of myeloid neoplasms and acute leukemias], acute megakaryocytic 
leukemia [AML-M7 type as per FAB or AML (megakaryoblastic) with t(1;22)(p13;q13); 
RBM15-MKL1 as per WHO 2008 revised classification] and acute leukemias of ambiguous 
lineage (as per WHO 2008 revised classification)], undergoing 7 + 3 remission IC with 
cytarabine and an anthracycline (daunorubicin or idarubicin). All cases have to be 
histopathologically confirmed by a diagnostic bone marrow biopsy. Use of granulocyte 
colony-stimulating factor (G-CSF) for any indication must have been discontinued at least 7 
days prior to entry into the study. 
 
3. Patients with secondary AML arising out of MDS (all subtypes under WHO classification), 
chronic myelomonocytic leukemia (CMML); therapy-related AML and those with a prior 
autologous hematopoietic cell transplantation are eligible. 
 
4. No morphological evidence of disease (defined as marrow myeloblast percentage of < 5% 
and/or documentation from hematopathologist indicating no morphological evidence of 
leukemia) on day 14 bone marrow examination (range, day 14-17; day 1 refers to the first 
day of IC) following remission IC. 
 
5. Must be able to give voluntary informed written consent to participate in the study. Informed 
consent will be obtained prior to starting remission IC (can be obtained even on the first day 
of remission IC if obtained before administration of chemotherapy) and before any study- 
related procedure not part of normal medical care, with the understanding that consent may 
be withdrawn by the subject at any time without prejudice to future medical care. 
 
6. Women of childbearing potential should be advised to avoid becoming pregnant and men 
should be advised to not father a child while receiving treatment. All men and women of 
childbearing potential must use acceptable methods of birth control throughout the study as 
described below: 
a) Females of childbearing potential: Recommendation is for 2 effective contraceptive 
methods during the study. Adequate forms of contraception are double-barrier 
methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
12 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
jelly or foam), oral, depo provera, or injectable contraceptives, intrauterine devices, 
and tubal ligation. 
b) Male patients with female partners who are of childbearing potential: 
Recommendation is for male and partner to use at least 2 effective contraceptive 
methods, as described above, during the study or to abstain. 
7. ECOG performance status of 0 to 2 (Appendix II). 
 
3.2 Exclusion Criteria 
 
1. Any serious medical condition, laboratory abnormality, or psychiatric illness that, in the view 
of the treating physician, would place the participant at an unacceptable risk if he or she were 
to participate in the study or would prevent that person from giving informed consent. 
 
2. Any active malignancy (unrelated, non-hematological malignancy) diagnosed within the 
past 12 months of starting the study drug (other than curatively treated carcinoma-in-situ of 
the cervix or non-melanoma skin cancer). 
 
3. Secondary AML arising out of myeloproliferative neoplasms [as per the revised 2008 WHO 
classification of myeloid neoplasms and acute leukemias] and MDS/MPD neoplasms other 
than CMML [as per the revised 2008 WHO classification of myeloid neoplasms and acute 
leukemias]. Refractory Anemia with Ringed Sideroblasts with thrombocytosis (RARS-T) 
classified as MDS/MPN neoplasm, unclassifiable will be excluded. AML patients with 
presenting features suspicious of underlying unrecognized MPD such as marked 
splenomegaly (> 20 cm) and thrombocytosis (>400,000 per microliter) will be excluded. 
Patients with relapsed or refractory AML will be excluded. 
 
4. Radiation therapy, cytotoxic chemotherapy, and combined modality (both radiation and 
chemotherapy) used to treat other cancers or medical conditions and administered within 6 
months prior to study enrollment. Use of hydroxyurea or emergent leukapheresis (for 
cytoreduction of highly elevated white blood cell counts) is permissible. Those AML 
patients who initially receive treatment with all-trans retinoic acid (ATRA) for presumptive 
diagnosis of APL but if APL is ruled out in final pathology will be eligible for the study. 
 
5. Prior history of treatment with recombinant TPO or TPO-R agonists. 
 
6. History of arterial or venous thrombosis [excluding line-thrombosis] within the last 1 year, or 
those with known inherited coagulopathies. Arterial or venous thrombosis includes 
pulmonary embolism, deep vein thrombosis of both upper [excluding line-thrombosis] and 
lower extremities, coronary artery disease managed medically or requiring intervention 
(percutaneous stent placement or coronary bypass surgery), cerebrovascular accident (for 
transient ischemic attacks clinical documentation is required), or involvement of other organs 
(such as hepatic, renal, spleen or other sites). 
 
7. Any evidence of fibrosis on morphological examination of bone marrow at the time of AML 
diagnosis. 
 
8. Concomitant participation in any other investigational treatment study. Simultaneous 
participation in non-therapeutic or observational studies will not be an exclusion criterion. 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
13 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
9. Uncontrolled intercurrent illness including, but not limited to uncontrolled infection, 
symptomatic or decompensated congestive heart failure, cardiac arrhythmia, unstable 
angina, cirrhosis or renal insufficiency (acute or chronic) on hemodialysis (at the time of 
diagnosis of AML). 
 
10. Liver enzymes (AST and ALT) > 3.5 times the upper limit of normal (ULN), and/or total 
bilirubin > 3.5 x ULN on the start day of eltrombopag unless considered due to Gilbert’s 
disease. 
 
11. A known immediate or delayed hypersensitivity reaction or idiosyncrasy that, in the opinion 
of the Medical Monitor is due to drugs chemically related to eltrombopag or excipients (e.g. 
mannitol). 
 
12. Known history of HIV or active hepatitis B or C. 
 
13. No major surgery within 2 weeks prior to study enrollment. 
 
14. Pregnancy or breast feeding 
 
15. Male and female patients who are fertile who do not agree to use an effective barrier 
methods of birth control (i.e. abstinence) to avoid pregnancy while receiving study 
treatment. 
 
 
3. 3 Enrollment of all Minority groups and Females 
 
The eltrombopag treatment will be offered to both genders and all racial and ethnic groups who 
meet the eligibility criteria of this clinical study. 
 
 
4.0 
STUDY DESIGN 
 
4.1 Overall Design 
 
This is a single institution, single arm, non-randomized phase II clinical trial with a sample size 
of 31 patients. The primary goal of this trial is to determine if eltrombopag can accelerate platelet 
count recovery in older AML patients (age > 60 years) who have no morphological evidence of 
leukemia in the bone marrow following remission IC. The standard remission IC for AML in 
patients > 60 years will consist of an anthracycline (daunorubicin or idarubicin) for 3 days and 
cytarabine as continuous intravenous infusion for 7 days. The patients in the study will receive 
supportive blood transfusions as part of standard of care at the Cleveland Clinic. Use of 
erythropoiesis stimulating agents (ESA) or granulocyte colony stimulating factors (G-CSF) 
during or following remission IC is not permitted. The study schema is shown below. 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
14 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
In those patients who have no morphologic evidence of disease on day 14 (range, 14-17) bone 
marrow evaluation, eltrombopag will be administered within 5 business days from the date of 
day 14 (range, 14-17) bone marrow biopsy. There will be a gap of at least one week (range, 7-9 
days) between the last day of remission IC and initiation of eltrombopag, which will allow 
sufficient time for complete washout of the chemotherapeutic agents. Dose modification will be 
determined based on platelet counts and presence of adverse event(s). 
 
5.0 
STUDY TREATMENTS 
5.1 Supplier 
 
Novartis will supply PROMACTA® (eltrombopag). 
5.2 Dosage Form 
 
Eltrombopag 200 mg once daily (two 100 mg tablets) has been selected as the starting dose for 
this study except for subjects of East Asian heritage who will start initially at 100 mg (one 100 
mg tablet) daily. The maximum dose of study medication is 300 mg once daily (three 100 mg 
tablets) for all subjects except for patients of East Asian heritage who will be escalated to a 
maximum of 150 mg (one 100 mg and one 50 mg tablet) daily. 
 
5.3. Pharmaceutical Presentation and Packaging 
 
White, round, film-coated tablets without debossing are provided, containing eltrombopag 
olamine equivalent to 100 mg of eltrombopag free acid. Tablets are packaged in white HDPE 
bottles with white plastic, induction-seal, and child-resistant caps. 
5.4 Storage and Handling 
 
The recommended storage condition is stated on the product label and, where required, the label 
also includes the expiry date. 
5.5 Receipt of Study Drug 
The Investigator or designee is responsible for taking an inventory of each shipment of 
PROMACTA® (eltrombopag) received, and comparing it with the accompanying study drug 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
15 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
accountability form. The Investigator will verify the accuracy of the information on the form, 
sign and date it, retain a copy in the study file, and return a copy to Novartis or its 
representative. The bottle numbers, if present, must be recorded when PROMACTA® 
(eltrombopag) is received and dispensed. 
 
5.6 Storage 
 
At the study site, the investigational study drug will be stored in a locked, safe area to prevent 
unauthorized access. PROMACTA® (eltrombopag) should be stored at room temperature away 
from direct sunlight and protected from excessive heat and cold. 
 
5.7 Unused Study Drug Supplies 
 
Novartis will instruct the Investigator on the return or destruction of unused PROMACTA® 
(eltrombopag). If any eltrombopag is lost or damaged, its disposition should be documented in 
the source documents. PROMACTA® (eltrombopag) study supplies will be retained at the 
clinical site pending instructions for disposition by Novartis. Participants will be instructed to 
return empty bottles and unused capsules. 
 
5.8 Drug Dispensing Requirements 
 
In investigational studies, eltrombopag will be dispensed through a qualified healthcare 
professional (including but not limited to, nurses, pharmacists and physicians). These healthcare 
professionals will be trained in requirements specific to counseling of subjects. Once trained 
these healthcare staff will counsel subjects prior to medication being dispensed to ensure that the 
subject has complied with all requirements including use of birth control and pregnancy testing 
and that the subject understands the risks associated with eltrombopag. In all females of child 
bearing age, negative result of required pregnancy testing will be verified and documented. 
 
5.9 Standard of Care Therapies 
 
Participants should receive all supportive care therapies (blood product transfusions, antibiotics, 
antiemetics, growth factors, etc.) that are required for treatment of the symptoms of disease or for 
infections or other adverse events. 
 
5.10 
Concomitant Medications and Non-drug Therapies 
 
5.10.1 Permitted Medications and Non-Drug Therapies 
 
A reasonable effort will be made to document any medications the subject received within the 30 
days prior to the first day in the study. If any medication is required at any time within 7 days 
before first day in the study through the completion of the short-term follow-up visit, subjects 
should consult the investigator. 
 
5.10.2. 
Use of Growth Factors 
 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
16 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
Subjects will not be allowed to receive granulocyte colony stimulating factor (G-CSF)/pegylated 
G-CSF, or other growth factors (e.g., epoetin alfa) during this study. Use of these drugs is not 
considered standard institutional practice at Cleveland Clinic during IC for AML. 
 
5.10.3. Food, Antacids, Cations and Vitamin/Mineral Supplements 
 
Eltrombopag should be taken on an empty stomach (1 hour before or 2 hours after a meal). 
Allow at least a 4 hour interval between eltrombopag and other medications or products 
containing polyvalent cations (e.g. calcium, magnesium, aluminum, zinc selenium or iron) such 
as antacids, dairy products, and mineral supplements to avoid significant reduction in 
eltrombopag absorption due to chelation. 
 
Administration of eltrombopag with a polyvalent cation-containing antacid decreased plasma 
eltrombopag exposure by 70%, and a similar reduction was observed when eltrombopag was 
administered with a high-calcium meal. Therefore, every effort must be made to educate subjects 
on how to take investigational product with medications or foods containing these polyvalent 
cations. Details of these and all concomitant medications should be recorded in the CRF. 
 
Subjects requiring routine (e.g. daily) acid suppression should be encouraged to take H2 
antagonists like ranitidine, famotidine or nizatidine, or proton pump inhibitors like omeprazole, 
esomeprazole or lansoprazole. Subjects requiring occasional acid suppression may take liquid or 
chewable antacids (calcium carbonate, aluminum hydroxide or magnesium hydroxide), provided 
investigational product is taken at least 4 hours before and 4 hours after consumption of cation- 
containing antacids. 
 
Mineral supplements (such as calcium, magnesium, aluminum, zinc, selenium or iron) are 
permitted during the study but investigational product must be taken at least 4 hours before and 4 
hours after consumption of these supplements. Similarly, eltrombopag must be taken at least 4 
hours before and 4 hours after consumption of dairy products (such as milk, yogurt, and cheese). 
 
5.10.4. HMG-CoA Reductase Inhibitors (statins) 
 
Subjects will be permitted to use HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-CoA) 
inhibitors during the study, but these drugs should be used with caution and a 50% dose 
reduction of the HMG-CoA reductase inhibitor is recommended, with close monitoring for 
safety, such as liver chemistry and signs and symptoms of myolysis, and efficacy, such as 
cholesterol and triglycerides (refer to individual product information for monitoring 
recommendations). 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
17 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
Preclinical data showed that eltrombopag is an inhibitor of the transporters OATP1B1 and 
BCRP. Therefore, a clinical drug interaction study to evaluate the impact of eltrombopag on the 
PK of rosuvastatin, an OATP1B1 and BCRP substrate, was conducted in healthy subjects. Co- 
administration of eltrombopag 75 mg once daily for 5 days with a single 10 mg dose of 
rosuvastatin administered on Day 5 increased plasma rosuvastatin Cmax 2.03-fold and AUC (0- 
∞) 55%. Concomitant administration of eltrombopag and other OATP1B1 or BCRP substrates 
should be used with caution. 
 
5.10.6. Blood product transfusions 
 
Transfusion of blood products will be allowed as per the Cleveland Clinic institutional 
guidelines. For details please refer to section 4.1. 
 
6.0. SAFETY DATA AND ASSESSMENT 
 
6.1. Common Side Effects and Toxicities (Reference: Eltrombopag Investigator Brochure) 
 
A detailed description of safety profile of eltrombopag in clinical pharmacology studies as well 
as in clinical trials involving patients with chronic liver disease, ITP and Hematology/Oncology 
related thrombocytopenia studies is available in the Clinical Investigator’s Brochure  provided 
by Novartis. The drug related toxicity will be scored based on the National Cancer Institute 
Common Toxicity Criteria Scale Version 4, which can be obtained from the CTEP website 
(http://ctep.cancer.gov/reporting/ctc.html). The effectiveness and safety of eltrombopag have 
not been established for use in other thrombocytopenic conditions including chemotherapy-
induced thrombocytopenia, myelodysplastic syndromes (MDS) and AML. 
 
6.2 Hepatic monitoring 
 
Eltrombopag administration can cause hepatobiliary laboratory abnormalities. In clinical studies 
in chronic ITP with eltrombopag, increases in serum alanine aminotransferase (ALT), aspartate 
aminotransferase (AST) and indirect bilirubin were observed. These findings were mostly mild 
(Grade 1-2), reversible and not accompanied by clinically significant symptoms that would 
indicate impaired liver function. In two placebo controlled studies in chronic ITP, adverse events 
of ALT increase were reported in 5.7 % and 4.0 % of eltrombopag and placebo treated patients 
respectively. In 2 controlled clinical studies in thrombocytopenic patients with HCV, ALT or 
AST > 3 x ULN were reported in 34 % and 38 % of the eltrombopag and placebo groups, 
respectively. Eltrombopag administration in combination with peginterferon/ribavirin therapy is 
associated with indirect hyperbilirubinaemia. Overall, total bilirubin ≥ 1.5 x ULN was reported 
in 76 % and 50 %of the eltrombopag and placebo groups, respectively. Serum ALT, AST, and 
total bilirubin should be measured prior to initiation of eltrombopag. If total bilirubin is elevated, 
fractionation should be performed. If the abnormalities are confirmed, serum hepatic function 
tests will be monitored daily inpatient as part of standardized care and once weekly as outpatient 
until the abnormalities are resolved, stabilized or returned to baseline levels. 
 
6.3 Thrombotic/Thromboembolic Complications 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
18 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
 
 
Platelet counts above the normal range present a theoretical risk for thrombotic/thromboembolic 
complications. In eltrombopag clinical trials in ITP thromboembolic events were observed at low 
and normal platelet counts. Use caution when administering eltrombopag to patients with known 
risk factors for thromboembolism (e.g., Factor V Leiden, ATIII deficiency, antiphospholipid 
syndrome). Platelet counts should be closely monitored and consideration given to reducing the 
dose or discontinuing eltrombopag treatment if the platelet count exceeds the study target levels. 
In ITP studies, 21 thromboembolic/thrombotic events were observed in 17 out of 446 subjects 
(3.8 %). The TEE events included: embolism including pulmonary embolism, deep vein 
thrombosis, transient ischemic attack, myocardial infarction, ischemic stroke, and suspected 
PRIND (prolonged reversible ischemic neurologic deficiency). Eltrombopag should not be used 
in patients with hepatic impairment (Child-Pugh score ≥ 5) unless the expected benefit 
outweighs the identified risk of portal venous thrombosis. In 2 controlled studies in 
thrombocytopenic patients with HCV receiving interferon based therapy, 31 out of 955 subjects 
(3 %) treated with eltrombopag experienced a TEE (3 %) and 5 out of 484 subjects (1 %) in the 
placebo group experienced TEEs. Portal vein thrombosis was the most common TEE in both 
treatment groups (1 % in patients treated with eltrombopag versus < 1 % for placebo). No 
specific temporal relationship between start of treatment and event of TEE were observed. The 
majority of TEEs resolved and did not lead to the discontinuation of antiviral therapy. In a 
controlled study in thrombocytopenic patients with chronic liver disease (n = 288, safety 
population) undergoing elective invasive procedures, the risk of portal vein thrombosis was 
increased in patients treated with 75 mg eltrombopag once daily for 14 days. Six of 143 (4 %) 
adult patients with chronic liver disease receiving eltrombopag experienced thromboembolic 
events (all of the portal venous system) and two of 145 (1 %) subjects in the placebo group 
experienced thromboembolic events (one in the portal venous system and one myocardial 
infarction). Five eltrombopag treated subjects with a TEE experienced the event within 14 days 
of completing eltrombopag dosing and at a platelet count above 200,000/µl. 
 
6.4 Bleeding Following Discontinuation of eltrombopag 
 
Following discontinuation of eltrombopag, platelet counts return to baseline levels within 2 
weeks in the majority of patients, which increases the bleeding risk and in some cases may 
lead to bleeding. Assessment of bleeding will be performed throughout the study from screening 
until the last dose of study drug or patient withdrawal from the study. Bleeding will be assessed 
by the WHO Bleeding Scale (Appendix V: WHO Bleeding Scale). Platelet counts will be 
monitored as part of daily CBC measurements during the period of hospitalization and thereafter 
once weekly as outpatient following discharge for 4 weeks following discontinuation of 
eltrombopag. 
 
6.5 Bone Marrow Reticulin Formation and Risk of Bone Marrow Fibrosis 
 
Thrombopoietin (TPO) receptor agonists, including eltrombopag, may increase the risk for 
development or progression of reticulin fibrosis within the bone marrow. Baseline information 
on bone marrow reticulin fibrosis is routinely obtained as part of bone marrow evaluation at the 
time of AML diagnosis at Cleveland Clinic. Prior to initiation of study medication, the peripheral 
blood smear will be examined to establish a baseline level of cellular morphologic abnormalities. 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
19 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
A follow up peripheral blood and bone marrow smear for any new or worsening morphological 
abnormalities (e.g., teardrop and nucleated red blood cells, immature white blood cells) will be 
performed at 6 week time point (from IC) when the remission status is routinely assessed (i.e. 
day ~30-45 bone marrow). If any new abnormalities are detected, additional bone marrow 
biopsies will be performed at periodic intervals based on clinical judgment. 
 
6.6 Malignancies and progression of malignancies 
 
There is a theoretical concern that TPO-R agonists may stimulate the progression of existing 
hematological malignancies such as MDS. Across the clinical trials in ITP (n = 493) and HCV 
(n = 1439) no difference in the incidence of malignancies or hematological malignancies was 
demonstrated between placebo and eltrombopag treated patients. This is consistent with 
information derived from non-clinical research, where no malignant cell proliferation has been 
demonstrated upon co-incubation of eltrombopag with MDS cell lines, multiple leukemic cell 
lines and solid tumor cell lines (colon, prostate, ovary and lung). 
 
6.7 Cataracts 
 
Cataracts were observed in toxicology studies of eltrombopag in rodents. Routine monitoring of 
patients for cataracts is recommended. In controlled studies in thrombocytopenic patients with 
HCV receiving interferon based therapy (n = 1439), progression of pre-existing baseline 
cataract(s) or incident cataracts was reported in 8 % of the eltrombopag group and 5 % of the 
placebo group. Screening ophthalmic assessments will be performed in those patients who 
complain of new or recent onset of visual symptoms or visual impairment at the time of AML 
diagnosis or those with known prior or existing ocular conditions. Ocular conditions that will 
need baseline evaluation include any vitreoretinal diseases, age-related macular degeneration, 
optic nerve disease, glaucoma and corneal diseases as well as patients in whom cataracts are 
clinically suspected. In those cases, a detailed ocular examination will be performed by an 
ophthalmologist and will include check for refractive errors, slit-lamp examination of anterior 
ocular structures, slit-lamp biomicroscopy of posterior pole and indirect ophthalmoscopy. 
Subsequent assessments including follow up exams will be performed if clinically indicated. For 
patients developing ocular symptoms during eltrombopag therapy, a detailed assessment will be 
carried out as mentioned earlier and will be documented as adverse effect. The baseline 
ophthalmic assessments where indicated needs to be completed prior to administration of the 
study drug. 
 
6.8 Risk of QT/QTc Prolongation 
 
There is no indication of a QT/QTc prolonging effect of eltrombopag at doses up to 150 mg daily 
for 5 days. The effects of PROMACTA at doses up to 150 mg daily for 5 days on the QT/QTc 
interval was evaluated in a double-blind, randomized, placebo- and positive-controlled 
(moxifloxacin 400 mg, single oral dose) crossover trial in healthy adult subjects. Assay 
sensitivity was confirmed by significant QTc prolongation by moxifloxacin. A 12-lead ECG will 
be obtained for each patient at screening (baseline). A pre- and post-dose 12-lead ECG will be 
performed. The post-dose ECG is to be performed within a 2-4 hour window post-dose 
(preferably within 3 hours after administration of study medication). If assessment cannot be 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
20 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
performed at 3 hours post-dose, record actual time of ECG performed. Thereafter, ECG will be 
performed if clinically indicated. 
 
7.0. TREATMENT PLAN 
 
7.1. Eltrombopag Administration 
 
Consecutive eligible patients will receive eltrombopag at an initial oral dose of 200 mg once 
daily. For patients of East-Asian heritage (Japanese, Chinese, Thai, Taiwanese and Korean), the 
starting dose will be 100 mg orally once a day. 
 
7.2. Dose Rationale 
 
Eltrombopag 200 mg once daily has been selected as the starting dose for this study (100 mg for 
subjects of East Asian heritage). The maximum dose of study medication is 300 mg once daily 
(150 mg in subjects of East Asian heritage). The rationale for allowing dose titration up to 
300 mg once daily is based on the following considerations: 
 
 The effective dose for eltrombopag for AML patients with chemotherapy-induced 
thrombocytopenia is unknown, and 300 mg is the maximum dose that is currently being 
considered in the eltrombopag clinical program, as described in the CIB.(11) 
 
 In a placebo-controlled Phase II study (NCT00102726) in 183 cancer patients receiving 
carboplatin and paclitaxel, eltrombopag was dosed at 50 mg, 75 mg and 100 mg with 
placebo as control arm in 1:1:1:1 ratio ) for 10 days after carboplatin and paclitaxel 
administration for up to 8 cycles. Eltrombopag was generally well tolerated as described 
in the CIB. (11). The study results for the 100 mg group demonstrated that there was 
evidence for increased platelet production in all three treatment arms after the nadir, with 
a gradual rise in platelet counts from Day 8 to 18 of chemotherapy. No apparent safety 
issues at 100 mg were identified.(28) 
 
 In a Phase II, non-randomized, open label pilot study of eltrombopag in aplastic anemia 
patients treated with immunosuppressive therapy and with refractory thrombocytopenia 
(NCT00922883), no observed toxicities were reported in this study to date with 
intrasubject dose escalation of eltrombopag starting at 50 mg and going up to 150 
mg.(29) The higher dose was continued in an extension phase. Improvements of both 
platelet and erythrocyte values have been observed following eltrombopag exposure in 
these patients. 
 
 In ITP subjects, a dose exposure and response relationship has been seen for eltrombopag 
doses of 30 mg to 75 mg once daily. There was no significant difference between the 
safety profile of ITP subjects receiving 30, 50 or 75 mg of eltrombopag when 
administered for up to 6 weeks. 
 
 In HCV subjects, a dose, exposure and response relationship has been seen for 
eltrombopag doses of 30 mg to 75 mg once daily, with geometric mean AUC (0-) 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
21 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
approximately 2-fold higher than that observed in ITP patients at the same dose. There 
was no significant difference between the safety profile of HCV subjects receiving 30, 50 
or 75 mg of eltrombopag, and the frequency of adverse events in these subjects did not 
increase in a dose-dependent manner. Two Phase III studies have recently completed 
(TPL103922/ENABLE 1 and TPL108390/ENABLE 2) in subjects with HCV-related 
thrombocytopenia and led to its FDA approval in November of 2012. The pooled data 
from these studies demonstrates that eltrombopag treatment increased platelet counts in 
thrombocytopenic subjects with HCV infection to a level sufficient to allow initiation and 
maintenance of antiviral therapy for subjects who would otherwise be ineligible or poor 
candidates for peginterferon-based antiviral therapy. Such antiviral therapy plus 
eltrombopag enabled 21% of patients to achieve a sustained viral response (SVR) rate; 
13% of subjects in the control arm (which also included eltrombopag during the OL 
Phase of the study) achieved an SVR. The results were statistically significant. 
 
 In vitro, there is a clear relationship between the eltrombopag concentration and the anti- 
proliferative effect of eltrombopag on leukemic cells.(11-13) Based on preliminary PK 
from Part 1 of this study, it is expected that doses of 200 to 300 mg eltrombopag will 
result in plasma concentrations at or above the in vitro IC50 values demonstrating anti- 
leukemic effects in preclinical experiments for the majority of the eltrombopag dosing 
interval. 
 
 In healthy subjects, a clear dose, exposure and response relationship has been seen for 
eltrombopag doses of 10 mg to 200 mg administered once daily for 5 days. Eltrombopag 
was well tolerated in healthy subjects at all dose levels. A starting dose of 100 mg once 
daily eltrombopag (50mg for East Asians) has been studied in 46 subjects with 
chemotherapy-induced thrombocytopenia. No apparent safety issues at 100 mg were 
identified. 
 
 Based on the PK in subjects with chemotherapy-induced thrombocytopenia (solid 
tumors), and anticipating similar PK in patients with hematologic malignancies, the 
predicted exposure in subjects with MDS or AML receiving 300 mg eltrombopag is 
expected to average 358 ug.h/mL at steady-state (typical 50 year old male subject), with 
significant intersubject variability. This is the similar to the exposure observed in patients 
with HCV receiving 75 mg eltrombopag. Covariates of exposures are gender, age, and 
East Asian Heritage. Scaling the exposure of subjects with solid tumors enrolled in the 
100 mg dose group to a dose of 300 mg results in an average exposure of 513µ g.h/mL, 
51% higher than the exposure observed in patients with HCV receiving 75 mg 
eltrombopag. 
 
 Preliminary results of a Phase II, multicenter, prospective, placebo-controlled, single 
blind study of eltrombopag (EQoL-MDS) administered at a 50 mg initial daily initial 
dose with increased every 2 weeks in low and intermediate-1 risk adult MDS patients 
with PLT count <30 Gi/L suggest safety of eltrombopag in terms of drug-related adverse 
events and disease progression. In such patients, eltrombopag treatment is effective in 
raising PLT counts and in reducing the risk of bleeding and is associated with significant 
improvements in quality of life.(30) 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
22 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
 
 
 There is evidence that higher doses of growth factors are required in subjects with cancer: 
the effective erythropoietin (EPO) dose in MDS is several times higher than the doses 
used in renal anemia.(1,14,16, 31-34) Anticipating impaired absorption and 
bioavailability of orally administered eltrombopag in AML patients resulting from 
mucositis of the gastro-intestinal tract, an often observed side effect of intensive 
remission IC, we plan to administer higher doses than have been utilized in other non- 
oncologic settings. 
 
 To ensure subject safety, the current study uses a dose escalation scheme in which 
subjects are exposed to the lowest dose necessary to achieve the desired platelet count 
target. Only subjects who have tolerated the previous dose and have not yet benefited 
from study medication will be considered for the next highest dose, dependent on platelet 
counts. This approach minimizes potential risks while allowing the subject the maximum 
potential for benefit. 
 
 Modified dosing for subjects of East Asian heritage has been implemented for the 
following reasons. In healthy Japanese subjects, plasma eltrombopag AUC (0-) was 
approximately 80% higher when compared to non-Japanese healthy subjects who were 
predominantly White. Similarly, in patients with ITP, plasma eltrombopag exposure was 
approximately 70% higher in East Asian subjects as compared to non–East Asian 
subjects who were predominantly White. 
 
 There are limited data on the use of eltrombopag in patients aged 65 years and older. In 
the clinical studies of eltrombopag, overall no clinically significant differences in safety 
of eltrombopag were observed between subjects aged at least 65 years and younger. 
 
7.3 Dose Adjustments for Eltrombopag 
 
If after 2 weeks, the platelet count fails to reach 50,000/µ L or above, the dose will be increased 
to 300 mg orally daily (150 mg orally daily for East-Asians). Depending on tolerability, dose 
modification will be individualized based on the patient’s platelet count response according to 
the following rules: 
 
 
Dose Modification / Adjustment of Eltrombopag 
If platelet count is < 50,000/µL after 2 weeks of 
treatment with starting dose of eltrombopag* 
Increase daily dose to 150 mg for East 
–Asians and 300 mg for all other 
ethnicities 
If platelet counts are between 50,000 and < 
100,000/µL (untransfused) on the starting or escalated 
dose of eltrombopag 
Continue on the same dose 
If platelet counts reach ≥ 100,000/µL (untransfused) 
on the starting or escalated dose of eltrombopag at any 
time on study 
Discontinue eltrombopag 
* Starting dose will be 100 mg for East-Asians and 200 mg for other ethnicities. 
 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
23 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
7.4 Dose delays, modifications or discontinuation for non-hematologic side effects 
 
7.4.1 Infection: Subjects who experience an infection requiring intravenous antibiotics will not 
have eltrombopag discontinued. If the subject experiences infection severe enough to require 
vasopressors or intubation, the drug will be withheld until the patient is stable. 
 
7.4.2 Liver function abnormalities: In the event of an increase in the ALT level to ≥3 times the 
ULN in patients with normal liver function or > 3X baseline in patients with elevations in 
transaminases before treatment, eltrombopag will be discontinued until ALT is < 2.5 times the 
ULN or from baseline. For all patients (whether on starting dose or escalated dose prior to 
discontinuation), eltrombopag will be restarted at the starting dose. Eltrombopag will be 
discontinued permanently if the toxicity reappeared on the starting dose. Other criteria for 
permanent discontinuation of eltrombopag will be if ALT levels increase (≥3 times the ULN in 
patients with normal liver function or ≥3X baseline in patients with elevations in transaminases 
before treatment] and are: 
- progressive, or 
- persistent for ≥ 1 week, or 
- accompanied by increased direct bilirubin, or 
- accompanied by clinical symptoms of liver injury or evidence for hepatic decompensation 
 
7.4.3 Cardiac arrhythmia: Onset of new onset arrhythmias during treatment with eltrombopag 
that can be adequately managed will not be a reason for discontinuation of eltrombopag. In 
patients with normal baseline QTc intervals (prior to starting eltrombopag), a QTc prolongation 
of > 500 milliseconds (ms) will be a reason for temporarily discontinuing eltrombopag only if no 
other secondary etiology (electrolyte abnormalities or other concomitantly administered QTc 
prolonging drugs) could be identified and corrected. If QTc prolongation of > 500 ms is 
clinically attributed to eltrombopag, then EKG should be checked daily till QTc returns to 
baseline and eltrombopag can be resumed at the discontinued dose. If QTc > 500 ms occurs 
following reintroduction of eltrombopag, then eltrombopag should be permanently discontinued. 
 
7.4.5 Renal impairment: No dose adjustments or discontinuation of eltrombopag is necessary in 
patients who develop acute kidney injury (with or without hemodialysis support) during 
remission IC or while on eltrombopag. 
 
7.5 Dose delays, modifications or discontinuation for hematologic side effects 
 
7.5.1 Thrombosis/Embolism: Subjects who experience a deep venous thrombosis (excluding 
line-related thrombus) or a pulmonary embolus, a TIA or stroke, or a myocardial infarction at 
any time while on eltrombopag will discontinue the drug and go off study. Patients with platelet 
counts of > 50,000/ul at the time of thrombosis will be treated with enoxaparin or another 
appropriate anticoagulant as clinically indicated. They will be treated for the thrombotic event as 
otherwise clinically-indicated. 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
24 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
7.5.2 Peripheral blood abnormalities: The development of significant worsening of anemia or 
neutropenia while on study will require discontinuation of eltrombopag and additional evaluation 
including a bone marrow biopsy as clinically indicated. 
 
7.6 Dosing Delays and Subject Replacement 
 
In case there is an interruption of treatment or if any medication dose is missed this would be 
captured and subsequently documented on the Dosage Administration Case Report Form (CRF). 
If the patient’s treatment is interrupted, the missed dose will not be replaced. If a patient misses a 
study dose due to noncompliance (as determined by the treating physician), then the patient 
would be removed from the study. Subsequently this subject would need to be replaced. If the 
treatment is interrupted for 1 week due to adverse effect(s) from study medication therapy, then 
the patient would be removed from the study and the subject(s) would not be replaced. 
 
7.7 Duration of Therapy and Off Study Criteria 
 
Depending on tolerability, eltrombopag can be administered to all assigned study subjects for a 
total duration of 4 weeks (counted from the first day of eltrombopag administration) unless they 
meet one of the following criteria for removal from the study: 
 
1. Withdrawal of consent. The patient's desire to withdraw from the study may occur at any 
time. The investigator should carefully consider whether the patient’s withdrawal of 
consent is due to an adverse event, and if so, record the adverse event as the reason for 
withdrawal. 
2. Violation of the study protocol, including a patient’s failure to return for required 
treatments or assessments or failure on the part of participants with reproductive potential 
to practice effective birth control or non-compliance. 
3. At the treating physician’s clinical discretion, if any specific medical or psychosocial 
changes in patient’s condition makes them unacceptable to further participate in the 
study. 
4. If bone marrow biopsy performed to establish remission status (around day 30-45 of 
remission IC), confirm refractory or persistent disease or if there is leukemic 
involvement of extramedullary site (biopsy confirmation of skin or organ lesions, central 
nervous system involvement confirmed either by cerebrospinal fluid analysis or 
radiological exams) at any time during study. 
5. Adverse events, including intolerance of eltrombopag not resolved by dose reduction, life 
threatening acute hypersensitivity reaction, persistent hepatotoxicity (refer to section 
7.4.2), thrombosis/embolism (DVT, PE, stroke, TIA, myocardial infarction) other than 
central line thrombosis (refer to section 7.5.1) or evidence of disease progression on 
treatment (myeloid sarcomas). Participants who are removed from the study due to 
adverse events will be treated and followed according to established medical practice. All 
pertinent information concerning the outcome of such treatment will be entered in the 
CRF. 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
25 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
7.8 Duration of Follow Up 
 
All study subjects who achieved a platelet count of 100,000/µL will be followed for a total up to 
4 weeks from the stop date of eltrombopag or till the start date of post-remission therapy, 
whichever occurs earlier, for adverse events and response. The patients who are removed from 
study for unacceptable adverse events will be followed until that adverse event is resolved or 
stabilized. All patients will thereafter be followed for 5 years from study enrollment for relapse 
and survival endpoints as part of institutional standard of care policy for all treated AML 
patients. 
 
8.0 CLINICAL MONITORING 
 
8.1 Pre-induction Evaluation 
 
Screening evaluation must be completed before starting remission IC and should include the 
following: 
1) A signed informed consent. 
2) Relevant medical history, including a detailed history for any antecedent hematologic 
disorder (AHD) and all treatments used for AHD including cytotoxic chemotherapy, 
radiation, or combined modality therapy. Review of all medications used during the 
4-week period prior to screening date will be done. 
3) CBC with differential at the time of diagnostic bone marrow biopsy for confirmation of 
AML. Documentation of all transfusions (red blood cells and platelets) along with dates 
of transfusion dating back to 8-weeks from the date of screening. 
4) Physical examination and vital signs, including measurement of blood pressure, pulse, 
respiratory rate, pulse oximetry (oxygen saturation), height and body weight. 
5) Assessment of ECOG performance status. 
6) Documentation of AML classification according to the revised WHO 2008 
classification. 
7) Peripheral blood smear. 
8) Bone marrow aspiration and biopsy for the following studies: cytologic analysis; 
morphologic assessment; flow cytometry assessment of marrow aspirate; CD34 
immunostaining where necessary to enumerate marrow myeloblasts; metaphase 
cytogenetics;  mutational analysis (especially c-kit mutations in favorable risk AML 
and NPM1, FLT3 and CEBPA mutations in patients with normal cytogenetics); and 
assessment of bone marrow fibrosis with reticulin and collagen staining. All these tests 
are currently done as routine standard of care. The results of mutational studies and 
metaphase cytogenetics are not necessary for starting patient on the study drug. 
9) Comprehensive metabolic panel evaluations, including blood glucose, total protein, 
albumin, creatinine, blood urea nitrogen (BUN), serum bicarbonate (CO2), calcium, 
phosphorus, sodium, potassium, chloride, aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), total bilirubin and alkaline phosphatase. 
10) Remote hepatitis panel. ELISA for HIV. 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
26 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
11) A 12-lead electrocardiogram (ECG), following at least a 5-minute rest in supine 
position. 
12) Baseline ophthalmological examination to be performed only in those presenting with 
new symptoms of visual impairment or insufficiency at the time of diagnosis of AML 
or those with known ocular conditions with accompanying vision defects. 
13) Chest x-ray (2 views – PA and lateral), unless a previous x-ray taken during the 4 
weeks prior to Day 1 of remission IC is available and shows no significant abnormality 
that would exclude the patient from the study. 
14) Male participants with female partners of childbearing potential should have 
contraceptive measures addressed at screening, sufficient time to employ required 
contraceptive measures prior to Day 1 of IC, and confirmation of adequacy of 
contraceptive measures prior to receiving study drug. 
15) Serum pregnancy test for women of childbearing status 
 
8.2 Monitoring while taking eltrombopag 
 
The following procedures will be conducted: 
1) Daily vital signs and physical exam while inpatient and once weekly as outpatient only in 
those patients still receiving eltrombopag. 
2) Adverse event (AE) monitoring and documentation will begin starting from the date of 
study drug initiation. Any AE resulting during or following remission IC but preceding 
study drug initiation will not be attributable to the study drug. AE’s will be recorded as 
definite, probable, possible, unlikely or unrelated by the treating team in the daily 
clinical progress note and abstracted for study documentation by approved study 
personnel (physicians, research nurses and study coordinators). 
3) CBC with differential will be monitored daily during hospital stay. Once the patient is 
discharged, CBC with differential will be checked within 72 hours, thereafter CBC with 
differential will be checked weekly until the subject’s platelets reach 100,000/µL.  
4) Complete metabolic panel (CMP) will be checked daily during hospital stay. Once the 
patient is discharged, CMP will be checked weekly until the subject’s platelets reach 
100,000/µL. 
5) Documentation of all infections requiring treatment with intravenous antimicrobials 
(antibacterial, antiviral or antifungal) by date (the period to be covered for documentation 
purposes starts at day 1 of study drug administration). 
6) Concurrent medication review (with each clinical assessment) for the entire period on the 
study drug. 
7) Documentation of all red blood cell and platelet transfusions including dates of 
transfusion while on eltrombopag. 
8) 12 lead electrocardiograms pre- and post-dose on the first day of eltrombopag 
administration and thereafter only if clinically indicated. The post-dose ECG is to be 
performed within a 2-4 hour window post-dose (preferably within 3 hours after 
administration of study medication). If assessment cannot be performed at 3 hours post- 
dose, record actual time of ECG performed. 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
CONFIDENTIAL 
Version 6, May 14, 2018 
27 
 
 
 
9) All study subjects who achieve a platelet count of 100,000/µL will be followed for a total 
up to 4 weeks from the stop date of eltrombopag or till the start date of post-remission 
therapy, whichever occurs earlier, for adverse events and response. Adverse events that 
are related to the study drug (eltrombopag) will be followed through resolution or 
stabilization. CBCs and CMPs will be collected per standard of care as well as AEs for 4 
weeks after stopping eltrombopag or till the start date of post-remission therapy, 
whichever occurs earlier.   
 
8.3 
Short-term Safety Follow-up 
 
1) Bone marrow aspiration and biopsy typically between days 30-45 of IC to assess remission 
status and thereafter as deemed necessary guided by peripheral counts and or clinical 
judgment. 
2) Peripheral blood smear typically between day 30-45 of remission IC at the time of bone 
marrow biopsy performed to evaluate remission status and at the end of the study period 
(optional) based on clinical assessment. 
3) Concurrent medication review (with each clinical assessment) 
4) CBC with differential and CMP 
5) Adverse event (AE) monitoring and documentation 
6) Vital signs and physical exam 
7) Documentation of all red blood cell and platelet transfusions 
 
8.4 
Long-term Follow-up 
 
All participants, regardless of reason for discontinuation, will be followed for survival and for 
AML transformation (an increase of blasts to a level ≥ 20% in peripheral blood or bone marrow) 
for five years from study registration as part of standard of care for CCF leukemia patients.  

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
28 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
The following study calendar will be used: 
 
Pre- induction 
Week 1 
Week 2 
Week 3 
Week 4 
Week 5 
Week 6 
Inpatient/Outpatient 
Induction chemotherapy (IC) 
 
Study Medicationa 
 
Informed Consent 
X 
Demographicsb 
X 
Disease Characteristicsc 
X 
Transfusion Historyd 
X 
X 
X 
X 
X 
X 
X 
Review of concurrent 
medications 
X 
X 
X 
X 
X 
X 
X 
Physical Examinatione 
X 
X 
X 
X 
X 
X 
X 
CSBEf 
X 
X 
X 
X 
X 
X 
X 
Performance statusg 
X 
Hematologyh 
X 
X 
X 
X 
X 
X 
X 
Serum Biochemistryi 
X 
X 
X 
X 
X 
X 
X 
Chest x-ray 
X 
Peripheral Blood Smearj 
X 
X 
Bone marrow biopsyk 
X 
D14 - 17 
X 
Ophthalmology examl 
X 
12 lead ECG 
X 
Xm 
Adverse event monitoringn 
 
X 
X 
X 
X 
Pre-induction assessment refers to evaluation at the time of diagnosis of AML prior to start of remission induction 
chemotherapy. Weeks as enumerated in the table refer to the time from the start date (day 1) of remission induction 
chemotherapy. 
Week 1 is the week when the patient receives the standard 7+ 3 (cytarabine and anthracycline) remission induction chemotherapy 
a. Study Medication: Eltrombopag dose as assigned. The drug will be started within 5 business days from the date of day 14 bone marrow 
biopsy if the day 14 bone marrow biopsy (range, 14-17) shows no morphological evidence of leukemia and will be continued for a total of 4 
weeks unless discontinued earlier for reasons stated in the protocol. 
b. Demographics: Date of birth, race, ethnicity, and gender. 
c. Disease Characteristics: Date of AML diagnosis, AML category as classified by WHO, primary vs. secondary AML, type of secondary AML 
(antecedent hematologic disorder, therapy-related including prior radiation therapy and or cytotoxic chemotherapy for any condition). 
d. Transfusion History: Transfusion requirements of red blood cells and platelets up to 8 weeks prior to the diagnosis of AML and during hospital stay. 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
CONFIDENTIAL 
Version 6, May 14, 2018 
29 
 
 
 
 
e. Physical Examination: Weight, height (during screening only), body temperature (oral), blood pressure, pulse rate, respiratory rate and pulse oximetry 
(oxygen saturation). 
f: CSBE: Clinically Significant Bleeding Events includes hematuria, gastrointestinal bleed, retroperitoneal bleeding, intra-cranial bleed, epistaxis 
not controlled by conservative measures and muscle or soft tissue hematomas. CSBE will not include petechial skin rash, ecchymosis or mucosal 
petechiae. 
g. Performance Status as per ECOG scale. 
h. Hematology: CBC with differential will be monitored daily during hospital stay. Once the patient is discharged, CBC with differential will be 
checked within 72 hours, thereafter CBC with differential will be checked weekly until the subject’s platelets reach 100,000/µL. Once the platelet 
counts reach 100,000/µL, the labs will be done at the discretion of treating physician as part of routine standard of care.  
i. Serum Biochemistry: Complete metabolic panel (CMP) will be checked daily during hospital stay. CMP will include albumin, total protein, 
alkaline phosphatase, total bilirubin, SGOT[AST], SGPT[ALT], sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose, and calcium. 
Magnesium and phosphorus will be resulted if clinically indicated. Once the patient is discharged, CMP will be checked weekly until the subject’s 
platelets reach 100,000/µL. Once the platelet counts reach 100,000/µL, the labs will be done at the discretion of treating physician as part of 
routine standard of care. ELISA for HIV and remote hepatitis panel will be checked only once at the time of study screening (pre-induction).  
j. Peripheral Blood Smear: Will be performed prior to start of induction chemotherapy, typically between day 30 and 45 of induction 
chemotherapy while checking for remission status, and at the end of the study period (optional) based on clinical assessment. 
k. Bone marrow biopsy: Bone marrow evaluation will include cellularity analysis, morphological assessment of all three cell lineages, 
assessment of blast percentage, fibrosis and metaphase cytogenetics. Tests for molecular mutations and FISH studies will be done as necessary 
as part of standard of care where indicated. D14-17 denotes marrow evaluation between day 14 to 17 from the start date of IC to check for 
persistent disease. D30-45 denotes marrow evaluation typically between day 30 to 45 from the start date of IC to check for remission status or 
refractory disease. The need for additional bone marrow biopsies including end of study bone marrow biopsy will be determined clinically 
based on peripheral blood count abnormalities or morphology 
l: Ophthalmologic evaluation: Complaints of any new or recent onset visual symptoms at the time of AML diagnosis. Those with known prior 
or existing ocular conditions such as any vitreoretinal diseases, age-related macular degeneration, optic nerve disease, glaucoma and corneal 
diseases as well as patients in whom there is clinical suspicion of cataracts will be evaluated at baseline. A follow up exam will be done at 2 
months after stopping the drug if clinically indicated. 
m:A 12-lead ECG will be obtained for each patient at screening (baseline). A pre- and post-dose 12-lead ECG will be performed on the first 
day of eltrombopag administration. The post-dose ECG is to be performed within a 2-4 hour window post-dose (preferably within 3 hours 
after administration of study drug). Thereafter, 12 lead ECGs will be performed as clinically indicated. 
n: Adverse events that are related to the study drug (eltrombopag) will be followed through resolution or stabilization. 
 
 
 
 
 
 
 
 
 
 
 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
30 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
 
 
9 ANCILLARY LABORATORY RESEARCH STUDIES 
 
9.1 Collection of samples 
During the course of participating on this study, additional blood samples will be collected – 3 X 
5 cc (SST tubes) and 3 X 3 cc (3.2% sodium citrate tubes). 
 
9.2 Intended use: The following laboratory research studies will be done and will be correlated 
with the presence or absence of response. 
• Quantification of microvesicles at different time points of AML treatment - during remission 
IC and while on eltrombopag 
• Analysis of micro RNA (miRNA) in the microvesicles from different time points of AML 
treatment - during remission IC and while on eltrombopag. 
The different time points of assessment are as follows: 
1) At the time of diagnosis of AML but prior to initiation of remission IC 
2) At the time of day 14 bone marrow assessment (range, 14-17) following remission IC 
3) On day 3 (+/- 1 business day) of study drug treatment. 
4) On day 6 (+/- 1 business day) of study drug treatment. 
5) At the time of bone marrow biopsy to confirm CR (usually between days 30-45 of remission 
IC) 
 
9.3 Tracking: Samples will be ordered and tracked using Clinical Trial Draw – Specimen 
Processing Requisition Form which will accompany the specimen. Samples will not be sent 
outside CCF. 
 
9.4 Storage: Research samples will be stored with identifiers in the secure laboratory of the co- 
investigator, Dr. Keith McCrae. 
 
9.5 End of study procedures: Samples from consenting subjects will be stored until they are no 
longer of scientific value or if a subject withdraws consent for their continued use, at which time 
they will be destroyed. 
 
9.6 Loss or destruction of samples: Should we become aware that a major breech in our plan for 
tracking and storage of samples has occurred, the IRB will be notified. 
 
10.0 STUDY ENDPOINTS 
 
10.1.1 Primary endpoint 
 
The proportion of patients achieving a platelet count of > 50,000/µL by day 24 of IC on 
eltrombopag therapy. The treatment response parameters for platelet count recovery for this trial 
was derived from a cohort of 200 older AML patients (excluding acute promyelocytic leukemia 
and acute megakaryocytic leukemia) who underwent aggressive 7 + 3 cytarabine-based 
remission IC at the Cleveland Clinic between 2000 and 2011. The total CR rate in our historical 
cohort was 41%. 
 
The median time to CR (defined as the time from the start date of IC to the achieving CR per 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
31 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
IWG criteria) was 34 days (range, 14-66). The median time to reach platelet counts > 50,000/µL 
was 24 days (range, 17-57) from the start date of IC. 
 
10.1.2 Response to Eltrombopag 
 
Complete Response to eltrombopag will be defined as improvement in platelet count 
(independent of platelet transfusions) to ≥ 100,000 /µL with eltrombopag that lasts for at least 4 
weeks after discontinuation of eltrombopag. The date of achieving complete response to 
eltrombopag was defined as the first day of the four-week period with platelet count greater than 
100,000 /µL off eltrombopag and independent of platelet transfusions. If the patient with platelet 
counts > 100,000/µL transition to subsequent post-remission therapy within the 4-week timeframe 
of eltrombopag discontinuation, then that will be considered a complete response.  
 
Partial Response to eltrombopag will be defined as any improvement in platelet count to > 
50,000 /µL but less than 100,000 /µL despite use of the highest dose of eltrombopag for the entire 
duration of the study or drop in platelet counts to < 100,000 after achieving complete response 
(necessitating resumption of eltrombopag treatment).  
 
No response (NR) is defined as failure to fulfill the above criteria for either complete 
response or partial response after 8 weeks of eltrombopag therapy and despite use of 
maximal escalated dose of eltrombopag.  
 
10.2. Secondary endpoints 
 
1) Kinetics of megakaryocyte recovery: Parameters to be assessed will include median time to 
reach platelet count ≥ 50,000 /µ L and ≥ 100,000 /µ L, number of days of platelet transfusion, 
rates of platelet transfusion-independence, median time to reach platelet transfusion- 
independence and rates of CSBE. The initial time point for assessing different platelet recovery 
periods will be the first day of remission IC. The number of days of platelet transfusion will be 
defined as the total number of days in the cycle, beginning with the first day of study drug 
administration, in which a patient received transfusion. The time to transfusion-independent 
platelet recovery will be defined as the number of days from the first day of IC until the first of 
the 5 consecutive days with platelet count equal to or greater than 50,000 /µ L without a platelet 
transfusion. For patients who do not achieve platelet recovery before the end of the study, the 
time to platelet recovery will be censored on the last day of the study. CSBE refers to all 
bleeding events that require intervention including, but not limited to, transfusional support (red 
blood cells, platelets and other blood products such as fresh frozen plasma or cryoprecipitate). 
CSBE will include hematuria, gastrointestinal bleed, retroperitoneal bleed, intra-cranial bleed, 
uncontrolled epistaxis and muscle or soft tissue hematomas. 
 
2) Kinetics of granulocytic recovery: Parameters to be assessed will include the median time to 
reach absolute neutrophil count (ANC) equal to or greater than 500 /µ L (first of the five 
consecutive days with ANC > 500 / µ l) and the median time to reach ANC equal to or greater 
than 1000 /µ L (first of the five consecutive days with ANC > 1000 / µ l) counted from the first 
day of study drug administration. A neutrophil response will be defined as an absolute increase 
in ANC of more than 1000 /µ L within 4 weeks of remission IC. 
 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
32 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
3) Kinetics of erythrocytic recovery: Parameters to be assessed will include the median number 
of days needed to reach a hemoglobin level > 8g/dl (first of the 5 consecutive days with 
hemoglobin > 8g/dl) starting from the first day of study drug administration, maximal rise in 
hemoglobin level after achieving transfusion-independence and rates of red blood cell transfusion-
independence within 4 weeks of IC An erythroid response in patients with a pretreatment 
hemoglobin level of < 8 g/dL (transfusion-dependent) will be defined as an increase in the 
hemoglobin level by 1.5 g/dL or more without transfusion of packed red cells that is sustained for at 
least 2 weeks (from the start date of eltrombopag) or a 50% reduction in the number of units of 
packed red cells transfused in the 2 consecutive weeks following eltrombopag use compared to the 
transfusion requirement in the 2 weeks preceding use of the study drug.      
   
 
4) Characterization of platelet response to eltrombopag by AML subtype (WHO classification), 
etiology of AML (de novo versus secondary) and cytogenetic risk groups. 
 
5) Treatment/Disease outcomes: CR rates, time to attain CR, CRp rates, time to initiation of 
post-remission therapy, rates of refractory or persistent disease, survival and safety profile. 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
33 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
Safety will be evaluated from the incidence and severity of adverse events based on clinical 
assessment and laboratory evaluations, determined according to the Common Terminology 
Criteria for Adverse Events (CTCAE), version 4.0 of the National Cancer Institute (NCI) Cancer 
Therapy Evaluation Program (CTEP). Survival will be calculated from the day of study 
enrollment until the last follow-up or death. Disease-free survival will be calculated from the 
date of complete remission until relapse, the date of last follow-up, or death. 
 
Response criteria of AML patients to IC will be based on AML International Working Group 
(IWG) criteria (Appendix III). Modified AML response criteria include: morphologic leukemia 
free state, morphologic CR, cytogenetic CR, molecular CR and CRp. IWG criteria do not require 
presence of bone marrow cellularity (usually profoundly hypocellular from the effects of 
cytotoxic chemotherapy) or absence of dysplasia as a criterion for remission status. 
 
11.0 ADVERSE EVENTS 
 
The investigator or site staff will be responsible for detecting, documenting and reporting events 
that meet the definition of an adverse events (AE) or severe adverse events (SAE). 
 
11.1 Definition of an AE 
 
Any untoward medical occurrence in a subject or clinical investigation subject, temporally 
associated with the use of a medicinal product, whether or not considered related to the 
medicinal product. 
Note: An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use 
of a medicinal product. 
 
Events meeting the definition of an AE include: 
• Exacerbation of a chronic or intermittent pre-existing condition including either an increase in 
frequency and/or intensity of the condition 
• New conditions detected or diagnosed after investigational product administration even though 
it may have been present prior to the start of the study 
• Signs, symptoms, or the clinical sequelae of a suspected interaction 
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either investigational 
product or a concomitant medication (overdose per se will not be reported as an AE/SAE). 
 
“Lack of efficacy” or “failure of expected pharmacological action” per se will not be reported as 
an AE or SAE. However, the signs and symptoms and/or clinical sequelae resulting from lack of 
efficacy will be reported if they fulfill the definition of an AE or SAE. 
 
Events that do not meet the definition of an AE include: 
• Medical or surgical procedures (e.g., endoscopy, appendectomy); the condition that leads to the 
procedure is an AE. 
• Situations where an untoward medical occurrence did not occur (social and/or convenience 
admission to a hospital) 
• Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
34 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
• The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the subject’s condition. This 
includes hematologic abnormalities, as these will be related to the disease and/or the IC. 
 
 
Grading of Adverse Events 
1 
Mild 
Symptom barely noticeable to subject; does not influence 
performance or functioning. Prescription drug not ordinarily needed 
for relief of symptom but may be given because of personality of 
subject. 
2 
Moderate 
Symptom of a sufficient severity to make subject uncomfortable; 
performance of daily activities influenced; subject is able to 
continue in study; treatment for symptom may be needed. 
3 
Severe 
Symptom causes severe discomfort. May be of such severity that 
subject cannot continue. Severity may cause cessation of treatment 
with test drug; treatment for symptom may be given and/or subject 
hospitalized. 
4 
Life-
threatening 
Symptom(s) place the patient at immediate risk of death from the 
reaction as it occurred; it does not include a reaction that, had it 
occurred in a more serious form, might have caused death. 
 
Attribution of Adverse Events 
1 
Not related 
This category applies to those adverse events which, after careful 
consideration, are clearly and incontrovertibly due to extraneous 
causes (disease, environment, etc.) 
2 
Unlikely 
(must 
have two) 
In general, this category can be considered applicable to those adverse 
events which, after careful medical consideration at the time they are 
evaluated, are judged to be unrelated to the test drug. An adverse 
event may be considered unlikely if or when: 
1. It does not follow a reasonable temporal sequence from 
administration of the test drug. 
2. It could readily have been produced by the subject's clinical state, 
environmental or toxic factors, or other modes of therapy 
administered to the subject. 
3. It does not follow a known pattern of response to the test drug. 
4. It does not reappear or worsen when the drug is re-administered. 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
35 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
3 
Possibly 
(must 
have two) 
This category applies to those adverse events for which, after 
careful medical consideration at the time they are evaluated, a 
connection with the test drug administration appears unlikely but 
cannot be ruled out with certainty. An adverse event may be 
considered possibly related if or when: 
1. It follows a reasonable temporal sequence from administration of the 
test drug. 
2. It could not readily have been produced by the subject's 
clinical state, environmental or toxic factors, or other modes of 
therapy administered to the subject. 
3. It follows a known pattern of response to the test drug. 
4 
Probably 
(must 
have 
three) 
This category applies to those adverse events for which, after careful 
medical consideration at the time they are evaluated, are felt with a 
high degree of certainty to be related to the test drug. An adverse 
event may be considered probably related if or when: 
1. It follows a reasonable temporal sequence from administration of the 
test drug. 
2. It could not be reasonably explained by the known characteristics of 
the subject's clinical state, environmental or toxic factors, or other 
modes of therapy administered to the subject. 
3. It disappears or decreases on cessation or reduction in dose. There 
are important exceptions when an adverse event does not disappear 
upon discontinuation of the drug, yet drug-relatedness clearly exists 
(e.g., bone marrow depression, fixed drug eruptions, tardive 
dyskinesia). 
4. It follows a known pattern of response to the test drug. 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
36 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
 
5 
Definitely 
(must have 
all) 
This category applies to those adverse events which, the Investigator 
feels are incontrovertibly related to test drug. An adverse event may be 
assigned an attribution of definitely related if or when: 
1. It follows a reasonable temporal sequence from administration of the 
test drug. 
2. It could not be reasonably explained by the known characteristics of 
the subject's clinical state, environmental or toxic factors, or other 
modes of therapy administered to the subject. 
3. It disappears or decreases on cessation or reduction in dose with 
re-exposure to drug. (Note: this is not to be construed as requiring 
re-exposure of the subject, however, a category of definitely related 
can only be used when a recurrence is observed.) 
4. It follows a known pattern of response to the test drug. 
 
11.2 Definition of an SAE 
 
A serious adverse event is any untoward medical occurrence that, at any dose: 
a. Results in death 
b. Is life-threatening 
NOTE: The term “life-threatening” in the definition of “serious” refers to an event in which 
the subject was at risk of death at the time of the event. It does not refer to an event, which 
hypothetically might have caused death, if it were more severe. 
c. Requires hospitalization or prolongation of existing hospitalization 
NOTE: In general, hospitalization signifies that the subject has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for observation and/or 
treatment that would not have been appropriate in the physician’s office or out-patient setting. 
Complications that occur during hospitalization are AEs. If a complication prolongs 
hospitalization or fulfills any other serious criteria, the event is serious. When in doubt as 
to whether “hospitalization” occurred or was necessary, the AE should be considered 
serious. Hospitalization for elective treatment of a pre-existing condition that did not 
worsen from baseline is not considered an AE. 
d. Results in disability/incapacity, or 
NOTE: The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions. This definition is not intended to include experiences of relatively minor 
medical significance such as uncomplicated headache, nausea vomiting, diarrhea, influenza, 
and accidental trauma (e.g. sprained ankle) which may interfere or prevent everyday life 
functions but do not constitute a substantial disruption. 
e. Is a congenital anomaly/birth defect 
f. Medical or scientific judgment should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may not be immediately 
life-threatening or result in death or hospitalization but may jeopardize the subject or may 
require medical or surgical intervention to prevent one of the other outcomes listed in the above 
definition. These should also be considered serious. Examples of such events are invasive or 
malignant cancers, intensive treatment in an emergency room or at home for allergic 
bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
37 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
development of drug dependency or drug abuse. 
g. All Grade 4 non-hematologic laboratory abnormalities assessed using the National Cancer 
Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Serious 
hematologic AEs are not included in the definition of an SAE, as these are related to the disease and/or 
to the IC. 
h. Serious hematologic AEs except for unprovoked arterial and venous thromboembolic events 
are not included in the definition of an SAE, as these are related to the disease and/or to the IC. 
Superficial thrombophlebitis and central line associated thrombosis will not be considered SAE. 
 
11.3 Relationship to Investigational Product 
 
It is a regulatory requirement for investigators to assess relationship to investigational product 
based on information available. The assessment should be reviewed on receipt of any new 
information and amended if necessary. “A reasonable possibility” is meant to convey that there 
are facts/evidence or arguments to suggest a causal relationship. 
 
Facts/evidence or arguments that may support “a reasonable possibility” include, e.g., a temporal 
relationship, a pharmacologically-predicted event, or positive dechallenge or rechallenge. 
Confounding factors, such as concomitant medication, a concurrent illness, or relevant medical 
history, should also be considered. 
 
11.4 Laboratory and Other Safety Assessment Abnormalities Reported as AEs and SAEs 
 
Any abnormal laboratory test results (clinical chemistry, or urinalysis) or other safety 
assessments (e.g., ECGs, radiological scans, vital signs measurements), including those that 
worsen from baseline, and felt to be clinically significant in the medical and scientific judgment 
of the investigator are to be recorded as AEs or SAEs.0, with the exception of hematologic AEs. 
 
However, any clinically significant safety assessments that are associated with the underlying 
disease or with IC are not to be reported as AEs or SAEs, except for findings judged by the 
investigator to be more severe than expected for the subject’s condition or death. 
 
Data will be collected for typical disease-related events such as anemia, leucopenia, worsening 
of thrombocytopenia or infections. All events of possible drug-induced liver injury with 
hyperbilirubinemia (defined as ALT ≥2.5 x ULN plus bilirubin ≥2 x ULN and/or INR > 1.5 or 
ALT ≥2.5 x ULN) require reporting as an SAE. Bilirubin fractionation is performed if testing is 
available. If testing is unavailable and a subject meets the criterion of total bilirubin ≥2 x ULN, 
then the event is still reported as an SAE. If INR is obtained, include values on the SAE form. 
INR elevations >1.5 suggest severe liver injury. 
 
11.5 Disease-Related Events and/or Disease-Related Outcomes Not Qualifying as SAEs 
 
During the study period, the following conditions will not qualify as an AE or SAE provided 
they are not considered attributable to study medication: 
• Cases of disease progression. 
• New or worsened cytopenias even if they result in treatment, and/or hospital admissions. 
• Serious infections including neutropenic fever/neutropenic sepsis, line-infection, PCP 
pneumonia, Clostridium difficile infection 
• Neutropenic fever/neutropenic sepsis 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
38 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
• Red cell or platelet transfusions 
 
11.6 Pregnancy 
 
Any pregnancy that occurs during study participation must be reported. To ensure subject safety, 
each pregnancy must be reported to Novartis within 2 weeks of learning of its occurrence. The 
pregnancy must be followed up to determine outcome (including premature termination) and 
status of mother and child. 
 
Pregnancy complications and elective terminations for medical reasons must be reported as an 
AE or SAE. Spontaneous abortions must be reported as an SAE. Any SAE occurring in 
association with a pregnancy brought to the investigator’s attention after the subject has 
completed the study and considered by the investigator as possibly related to the investigational 
product, must be promptly reported to Novartis. In addition, the investigator must attempt to 
collect pregnancy information on any female partners of male study subjects who become 
pregnant while the subject is enrolled in the study. Pregnancy information must be reported to 
Novartis as described above. 
 
11.7 Time Period and Frequency of Detecting AEs and SAEs 
 
The investigator or site staff is responsible for detecting, documenting and reporting events that 
meet the definition of an AE or SAE. 
 
AEs will be collected from the start of Investigational Product and through the short-term follow 
up period. Treatment related AEs will be followed through resolution / stabilization, regardless if 
this requires clinical monitoring beyond the short-term follow up period. SAEs will be collected 
over the same time period as stated above for AEs. Any SAEs assessed as related to study 
participation (e.g., investigational product, protocol mandated procedures, invasive tests, or 
change in existing therapy) will be recorded from the time a subject consents to participate in the 
study; all SAEs will be followed through resolution. All SAEs will be reported to Novartis 
within 24 hours, as indicated. 
 
 
Novartis Reporting 
 
All serious adverse events must be reported by facsimile within 24 hours to Novartis at Fax 
#877-778-9739. Should the designated SAE fax number be non-functional, SAEs should be sent 
to the designated SAE mailbox: clinicalsafetyop.phuseh@novartis.com 
 
A Novartis SAE report coversheet should be included when reporting any SAE and must include 
the Novartis study number (CETB115DUS02T), the study title, investigator contact information, 
and a signature.  
 
Emergency or after-hours contact information  
Contact the page operator at (216) 444-2200 or toll free at (800) 223-2273, and ask for the 
oncologist (cancer doctor) that is on call.

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
39 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
The SAE report should comprise a full written summary, detailing relevant aspects of the 
adverse events in question. Where applicable, information from relevant hospital case records 
and autopsy reports should be included. Follow-up information should be forwarded to 
Novartis within 24 hours. 
 
SAEs brought to the attention of the investigator at any time after cessation of eltrombopag and 
considered by the investigator to be related or possibly related to eltrombopag must be reported 
to Novartis if and when they occur. Additionally, in order to fulfill international reporting 
obligations, SAEs that are related to study participation (e.g., procedures, invasive tests, change 
from existing therapy) or are related to a concurrent medication will be collected and recorded 
from the time the subject consents to participate in the study until he/she is discharged. 
 
FDA Reporting 
 
All SAEs that are unexpected (i.e., not in the current PROMACTATM (Eltrombopag) package 
inserts or the Investigator Brochures) and associated with use of the study drug must be reported 
to FDA within 15 calendar days, or within 7 calendar days if the SAE was fatal or life- 
threatening. Novartis will be responsible for FDA reporting of all necessary SAEs.  
 
11.8 Regulatory Reporting Requirements for SAEs 
 
Prompt notification of SAEs by the investigator to Novartis is essential so that legal obligations 
and ethical responsibilities towards the safety of subjects are met. 
 
The sponsor-investigator has a legal responsibility to notify both the local regulatory authority 
and other regulatory agencies about the safety of a product under clinical investigation. The 
sponsor-investigator will comply with specific regulatory requirements relating to safety 
reporting to the regulatory authority, /Institutional Review Board (IRB), Novartis, and sub- 
investigators. 
 
Investigator safety reports are prepared for suspected unexpected serious adverse reactions 
according to local regulatory requirements and Novartis policy and are forwarded to 
investigators as necessary. 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
40 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
An investigator who receives an investigator safety report describing an SAE(s) or other specific 
safety information (e.g., summary or listing of SAEs) from Novartis will file it with the CIB and 
will notify the IEC /IRB, if appropriate according to local requirements. 
 
12.0 STATISTICAL CONSIDERATIONS 
 
The primary goals of this trial are to assess the efficacy and safety of a short course of 
eltrombopag in elderly AML patients who have no morphological evidence of residual disease 
on bone marrow biopsy following standard 7+3 induction therapy. The primary endpoint is the 
proportion of patients with early (by day 24 from the start of induction) platelet recovery to 
>50,000/L. Based on historical data and our own institutional data (unpublished) approximately 
60% of patients can be expected to recover platelets to >50,000/L by day 24 without additional 
supportive care beyond platelet transfusions. An increase in the recovery rate to >80% would be 
considered indicative that eltrombopag has significant efficacy in this population. 
 
A two-stage accrual design with a maximum accrual goal of 31 eligible and evaluable patients 
will be used to test this hypothesis. Twelve eligible patients will be studied initially. If eight or 
more (67%) have full platelet recovery by day 24 an additional 19 eligible patients will be 
assessed. If overall 21 or more of the 31 patients have platelet recovery (observed recovery rate 
>68%) eltrombopag will be accepted for further testing. With this design, there is a >56% 
likelihood of stopping early if eltrombopag’s true recovery rate is <60%, whereas there is at most 
a 7% chance if the true recovery rate is >80%. The overall likelihood of rejecting eltrombopag if 
it is not active is >81% while there is at most a 9% chance of rejection if it is active. 
 
Adverse events will be graded and categorized using CTCAE version 4.03 criteria. Assuming the 
trial reaches its maximum accrual goal of 31 eligible patients the likelihood of a particular type 
and/or grade of toxicity will be estimable using a 95% confidence interval that has a half-width 
of at most 18%. The likelihood of observing at least one such event is > 80% even if the 
underlying risk is little as 5%. 
 
Secondary goals of the trial include estimating the frequency of platelet transfusion 
independence, the effect of eltrombopag on hemoglobin, and neutrophils, the risk of clinically 
significant bleeding, clinical efficacy, and time to initiation of post-remission consolidation 
therapy. 
 
In general categorical data will be summarized as frequency counts and percentages, measured 
(non-time dependent) data will be summarized as medians and ranges, and “time-to-event” data, 
such as platelet and neutrophil recovery, and time to CR will be summarized using the Kaplan- 
Meier method. Exploratory analyses (univariable) will utilize methods such as Fisher’s exact test 
and chi-square tests (categorical data), the Wilcoxon signed-rank, rank-sum, and Jonckheere- 
Terpstra tests (measured data), and the log rank test and proportional hazards models (time-to- 
event data). Logistic regression and proportional hazards models will be the primary tools used 
for any multivariable analyses performed. All tests of statistical significance will be two sided 
and in general no adjustment to p-values will be made for multiple comparisons due to the 
exploratory nature of these analyses. 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
41 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
 
 
13.0 REGULATORY CONSIDERATIONS 
Good Clinical Practice 
The study will be conducted in accordance with the International Conference on Harmonisation 
(ICH) for Good Clinical Practice (GCP) and the appropriate regulatory requirement(s). The 
investigator will be thoroughly familiar with the appropriate use of the drug as described in the 
protocol and Investigator’s Brochure. Essential clinical documents will be maintained to 
demonstrate the validity of the study and the integrity of the data collected. Master files should 
be established at the beginning of the study, maintained for the duration of the study and retained 
according to the appropriate regulations. This is the responsibility of the sponsor-investigator. 
 
Ethical Considerations 
 
The study will be conducted in accordance with ethical principles founded in the Declaration of 
Helsinki (see appendix). The IRB/IEC will review all appropriate study documentation in order 
to safeguard the rights, safety and well-being of the patients. The study will only be conducted at 
sites where IRB/IEC approval has been obtained. The protocol, Investigator’s Brochure, 
informed consent, advertisements (if applicable), written information given to the patients 
(including diary cards), safety updates, annual progress reports, and any revisions to these 
documents will be provided to the IRB/IEC by the investigator. Novartis requests that the 
protocol and informed consent documents be reviewed by Novartis or designee prior to IRB/IEC 
submission. 
 
Patient Information and Informed Consent 
 
The principles of informed consent are described by Federal Regulatory Guidelines (Federal 
Register Vol. 46, No. 17, January 27, 1981, part 50) and the Office for Protection from Research 
Risk Reports: Protection of Human Subjects (Code of Federal Regulations 45 CFR46). They 
must be followed to comply with FDA regulations for the conduct and monitoring of clinical 
investigations. 
 
Institutional Review 
 
This study must be approved by an appropriate institutional review committee as defined by 
Federal Regulatory Guidelines (Ref. Federal Register Vol. 46, 17, January 27, 1981, part 56) and 
the Office for Protection from Research Risks Reports: Protection of Human Subjects (Code of 
Federal Regulations 45 CFR 46). 
 
Patient Confidentiality 
 
In order to maintain patient privacy, all data capture records, drug accountability records, study 
reports and communications will identify the patient by initials and the assigned patient number. 
The investigator will grant monitor(s) and auditor(s) from Novartis or its designees and 
regulatory authority(ies) access to the patient’s original medical records for verification of data 
gathered on the data capture records and to audit the data collection process. The patient’s 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
42 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
confidentiality will be maintained and will not be made publicly available to the extent permitted 
by the applicable laws and regulations. 
 
Data Management 
 
Electronic Case Report Forms (eCRFs) will be developed to include all necessary patient 
information, laboratory data, treatment data, and adverse event data. This data will be housed 
securely within the web-based ONCORE database and will be password protected. The 
ONCORE database is 21 CFR Part 11 compliant. The Database Manager at CCF will train the 
data entry designee(s) on the ONCORE system. Upon completion of the training and electronic 
signature certification, the Database Manager will create a user account in ONCORE for the data 
entry designee(s). The data entry designee(s) will proceed with entering the patient(s) relevant 
information and eCRF forms. The Database Manager will periodically run reports across all 
studies to ensure timely and accurate entry of accrual data. 
 
Protocol Compliance 
 
The investigator will conduct the study in compliance with the protocol given approval/favorable 
opinion by the IRB/IEC and the appropriate regulatory authority(ies). Changes to the protocol 
will require approval from Novartis (changes are to be submitted by CCF) and written IRB/IEC 
approval/favorable opinion prior to implementation, except when the modification is needed to 
eliminate an immediate hazard(s) to patients. The IRB/IEC may provide, if applicable regulatory 
authority(ies) permit, expedited review and approval/favorable opinion for minor change(s) in 
ongoing studies that have the approval /favorable opinion of the IRB/IEC. The CCF Principal 
Investigator will submit all protocol modifications to Novartis and the regulatory authority(ies) 
in accordance with the governing regulations. All participating subsite(s) will contact the CCF 
study coordinator. Any departures from the protocol must be fully documented in the source 
documents. 
 
On-site Audits 
 
Regulatory authorities, the IEC/IRB, and/or Novartis may request access to all source 
documents, data capture records, and other study documentation for on-site audit or inspection. 
Direct access to these documents must be guaranteed by the investigator, who must provide 
support at all times for these activities. 
 
Drug Accountability 
 
Accountability for the drug at all study sites is the responsibility of the principal investigator. 
The investigator will ensure that the drug is used only in accordance with this protocol. Drug 
accountability records indicating the drug’s delivery date to the site (if applicable), inventory at 
the site (if applicable), use by each patient, and return to Novartis or disposal of the drug (if 
applicable and if approved by Novartis) will be maintained by the clinical site. Accountability 
records will include drug receipt/destruction dates, quantities, lot numbers, expiration dates (if 
applicable), and corresponding registered patient numbers. All material containing eltrombopag 
will be treated and disposed of as hazardous waste in accordance with governing regulations. 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
43 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
 
 
Premature Closure of the Study 
 
This study may be prematurely terminated, if in the opinion of the investigator or Novartis, 
there is sufficient reasonable cause. Written notification documenting the reason for study 
termination will be provided to the investigator or Novartis by the terminating party. 
Circumstances that may warrant termination include, but are not limited to: 
1. Determination of unexpected, significant, or unacceptable risk to patients 
2. Failure to enter patients at an acceptable rate 
3. Insufficient adherence to protocol requirements 
4. Insufficient complete and/or evaluable data 
5. Plans to modify, suspend or discontinue the development of the drug 
6. Should the study be closed prematurely, all study materials must be returned to Novartis 
 
Record Retention 
 
The sponsor-investigator will maintain all study records according to applicable Cleveland Clinic 
Foundation regulatory requirement(s). 
 
Patient Consent and Peer Judgment 
 
All institutional, NCI, FDA, state and Federal regulations concerning informed consent and peer 
judgment will be fulfilled. 
 
 
 
14.0 REFERENCES 
 
1. Surveillance Epidemiology and End Results (SEER) Program SEER Web site, Limited 
use-data (1973–2004). National Cancer Institute D, Surveillance Research Program, 
Cancer Statistics Branch. http://www.seer.cancer.gov. 
 
2. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world 
data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. 
Blood 2009;113:4179–4187. 
 
3. Pulte D, Gondos A, Brenner H, et al. Improvements in survival of adults diagnosed with 
acute myeloblastic leukemia in the early 21st century. Haematologica 2008;93:594–600. 
 
4. Lerch E, Espeli V, Zucca E, et al. Prognosis of acute myeloid leukemia in the general 
population: data from southern Switzerland. Tumori 2009;95:303–310. 
 
5. Alibhai SM, Leach M, Minden MD, et al. Outcomes and quality of care in acute myeloid 
leukemia over 40 years. Cancer 2009;115:2903–2911. 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
44 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
6. Walter RB, Kantarjian HM, Huang X et al. Effect of complete remission and responses 
less than complete remission on survival in acute myeloid leukemia: a combined Eastern 
Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer 
Center Study. J Clin Oncol 2010;28(10):1766-1771. 
 
7. Geddis AE, Linden HM, Kaushansky K. Thrombopoietin: a pan-hematopoietic cytokine. 
Cytokine Growth Factor Rev 2002;13:61–73. 
8. Debili N, Wendling F, Cosman D, et al. The Mpl receptor is expressed in the 
megakaryocytic lineage from late progenitors to platelets. Blood 1995;85:391–401. 
 
9. Wendling F. Thrombopoietin: its role from early hematopoiesis to platelet production. 
Hematologica 1999;84:158–166. 
 
10. Jenkins JM, Williams D, Deng Y, et al. Phase I clinical study of eltrombopag, an oral, 
nonpeptide thrombopoietin receptor agonist. Blood 2007;109:4739–4741. 
 
11. Eltrombopag Investigator Brochure, Edition 13, Date: 13-April-2016, Novartis 
 
12. Will B, Kawahara M, Luciano JP, et al. Effect of the non-peptide thrombopoietin 
receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid 
leukemia and myelodysplastic syndromes. Blood 2009;114(18):3899-3908. 
 
13. Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB- 
497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 2009;27:424- 
30. 
 
14. Mavroudi I, Pyrovolaki K, Pavlaki K, et al. Effect of the nonpeptide thrombopoietin 
receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk 
myelodysplastic syndrome. Leuk Res 2011;35(3):323-328. 
 
15. Roth M, Will B, Simkin G, et al. Eltrombopag inhibits the proliferation of leukemia cells 
via reduction of intracellular iron and induction of differentiation. Blood 
2012;120(2):386-394. 
 
16. Kalota A, Gewirtz AM. A prototype nonpeptidyl, hydrazone class, thrombopoietin 
receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells. Blood 
2010;115(1):89-93. 
 
17. Cairo MS. Dose Reductions and Delays: Limitations of Myelosuppressive 
Chemotherapy. Oncology (Williston Park) 2000;14:21-31. 
 
18. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction 
and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to 
platelet transfusions. N Engl J Med 1997;337:1861-1869. 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
45 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
 
 
19. Kerkhoffs JL, Eikenboom JC, van deWatering LM, et al. The clinical impact of platelet 
refractoriness: correlation with bleeding and survival. Transfusion 2008;48:1959. 
 
20. Heddle NaK, J ed. Febrile Nonhemolytic Transfusion Reactions. In: MA P ed. 
Transfusion Reactions. Bethesda, MD: AABB Press; 2001. 
 
21. Popovsky MA, Moore SB. Diagnostic and Pathogenetic Considerations in Transfusion- 
Related Acute Lung Injury. Transfusion 1985; 25:573-577. 
 
22. Silliman CC, Boshkov LK, Mehdizadehkashi Z, et al. Transfusion-Related Acute Lung 
Injury: Epidemiology and a Prospective Analysis of Etiologic Factors. Blood 
2003;101:454-462. 
 
23. Silliman CC, Paterson AJ, Dickey WO, et al. The Association of Biologically Active 
Lipids with the Development of Transfusion-Related Acute Lung Injury: A Retrospective 
Study. Transfusion 1997;37:719-726. 
 
24. Dodd RY, Notari EPt, Stramer SL. Current Prevalence and Incidence of Infectious 
Disease Markers and Estimated Window-Period Risk in the American Red Cross Blood 
Donor Population. Transfusion 2002;42:975-979. 
 
25. Fuller AK, Uglik KM, Savage WJ, et al. (2009) Bacterial Culture Reduces but does not 
Eliminate the Risk of Septic Transfusion Reactions to Single-Donor Platelets. 
Transfusion; 49:2588-2593. 
 
26. Eder AF, Kennedy JM, Dy BA, et al. Limiting and Detecting Bacterial Contamination of 
Apheresis Platelets: Inlet-Line Diversion and Increased Culture Volume Improve 
Component Safety. Transfusion 2009; 49:1554-1563. 
 
27. Kuter DJ. What is the potential for thrombopoietic agents in acute leukemia? Best Pract 
Res Clin Haematol 2011;24:553-558. 
 
28. Kellum A, Jagiello-Gruszfeld A, Bondarenko IN, et al. A Randomized, Double-Blind, 
Placebo-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of 
Eltrombopag in Patients Receiving Carboplatin/Paclitaxel for Advanced Solid Tumors. 
Curr Med Res Opin. 2010;26(10):2339-2346. 
 
29. Olnes MJ, Yong T, et al. Eltrombopag can Stimulate Trilineage Hematopoiesis In 
Patients with Refractory Severe Aplastic Anemia [abstract]. In: Blood (ASH Annual 
Meeting Abstracts) 2010 116: Abstract 4427. 
 
30. Oliva EN, Santini V, et al. Efficacy and Safety of Eltrombopag for the Treatment of 
Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: 
Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
46 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
(EqoL-MDS) [Abstract]. In Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 
633. 
 
31. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of Anemia in 
Myelodysplastic Syndromes with Granulocyte Colony-Stimulating Factor plus 
Erythropoietin: Results from a Randomized Phase II Study and Long-Term Follow-Up of 
71 Patients. Blood 1998;92:68-75. 
 
32. Procrit Package Insert; 2008. 
 
33. Epogen Package Insert; 2008. 
 
34. Aranesp Package Insert; 2008. 
 
Appendix I: WHO Bleeding Scale 
 
Modified Response Criteria 
Grade 0 
No bleeding 
Grade 1 
Petechiae 
Grade 2 
Mild blood loss 
Grade 3 
Gross blood loss 
Grade 4 
Debilitating blood loss 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
47 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
Appendix II: ECOG Performance Status 
 
Modified Response Criteria 
PS 0 
Fully active, able to carry on all pre-disease performance without 
restriction 
PS 1 
Restricted in physically strenuous activity but ambulatory and able to carry 
out work of a light or sedentary nature e.g. light house work, office work. 
PS 2 
Ambulatory and capable of all self-care but unable to carry out any work 
activities. Up and about more than 50% of waking hours. 
PS 3 
Capable of only limited self-care, confined to bed or chair more than 50% 
of waking hours. 
PS 4 
Completely disabled. Cannot carry on any self-care. Totally confined to 
bed or chair. 

Product: PROMACTA® eltrombopag 
CASE4913/IRB14-147 
48 
CONFIDENTIAL 
Version 6, May 14, 2018 
 
 
 
Appendix III: AML IWG Response Criteria (Cheson, 2003) 
 
Modified Response Criteria 
Morphologic leukemia- 
free state 
Bone marrow blasts <5% 
No extramedullary disease 
Morphologic CR 
Bone marrow blasts <5%; 
Neutrophils >1Gi/L; 
HI-P a b 
No extramedullary disease 
Cytogenetic CR 
As morphologic CR and normal cytogenetics 
No extramedullary disease 
Molecular CR 
As morphologic CR and no molecular mutations 
No extramedullary disease 
Partial remission 
Bone marrow blasts >50% or decrease to 5-25% (<5% if Auer 
rod positive) 
Neutrophils >1Gi/L; 
HI-P a b 
Modification to Cheson 2003. 
HI-P : Baseline <20Gi/L: >20 Gi/L and 2x baseline; Baseline ≥20 Gi/L: ≥50 Gi/L and 2x baseline